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Abstract

Overexpression of the hepatocyte growth factor receptor (c-Met) and its
ligand, the hepatocyte growth factor (HGF), and a constitutively active mutant of
the epidermal growth factor receptor (∆EGFR/EGFRvIII), occur frequently in
glioblastoma. c-Met is activated in a ligand-dependent manner by HGF or in a
ligand-independent manner by ∆EGFR. Dysregulated c-Met signaling contributes
to the aggressive phenotype of glioblastoma, yet the mechanisms underlying the
production of HGF in glioblastoma are poorly understood. We found a positive
correlation between HGF and c-Met expression in glioblastoma, suggesting that
they are coregulated. This is supported by the finding that in a c-Met/HGF axisdependent glioblastoma cell line, shRNA-mediated silencing of c-Met, or treatment
with the c-Met inhibitor SU11274, attenuated HGF expression. Biologically, c-Met
knockdown

decreased

anchorage-independent

colony formation

and

the

tumorigenicity of intracranial xenografts. Building on prior findings that ∆EGFR

viii

enhanced c-Met activation, we found that ∆EGFR also led to increased HGF
expression, which was reversed upon ∆EGFR inhibition with AG1478. ∆EGFR
required c-Met to maintain elevated HGF expression, colony formation of
glioblastoma cells, and the tumorigenicity of orthotopic xenografts. An unbiased
mass spectrometry-based approach identified phosphotyrosine-related signaling
changes that occurred with c-Met knockdown in a glioblastoma cell line
expressing ΔEGFR and in parental cells. Notably, phosphorylation of STAT3, a
master regulator of the mesenchymal GBM subtype and a known target of
∆EGFR, also decreased when c-Met was silenced in these cells, suggesting that
the signals from these receptors converge on STAT3. Using a STAT3 inhibitor,
WP1193, we showed that STAT3 inhibition decreased HGF mRNA expression in
ΔEGFR-expressing

glioblastoma

cells.

Consistent

with

these

findings,

constitutively active STAT3 partially restored HGF expression and anchorageindependent growth of c-Met knockdown glioblastoma cells that overexpressed
ΔEGFR. We found that higher levels of HGF and c-Met expression associated
with the mesenchymal GBM subtype. Taken together, these results suggest that
the activity of c-Met regulates the expression of HGF in glioblastoma cells, that
∆EGFR feeds positively into this autocrine loop, that signaling of the two receptors
together modulate HGF expression via STAT3, and that the HGF/c-Met axis may
therefore be a good additional target for therapy of mesenchymal GBM tumors.
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CHAPTER 1

INTRODUCTION

1

Glioma

Gliomas account for the majority of primary brain malignancies found in
adults (Sathornsumetee et al., 2007).

The main glioma subtypes include

astrocytomas, oligodendrogliomas, and ependymomas (Yan et al., 2009). The
most common group of gliomas are the astrocytomas, and are otherwise known
as glial tumors (Gonzalez and Gilbert, 2005). On the basis of pathology and
clinical criteria, the World Health Organization (WHO) classifies astrocytomas into
one of four grades; grades I through IV (Yan et al., 2009). Grade I astrocytic
tumors may be either pilocytic astrocytomas or subependymal giant cell
astrocytomas (Louis et al., 2007). These low-grade lesions are not aggressive,
are generally benign, and are typically cured by surgical resection (Yan et al.,
2009). Grade II astrocytic tumors include pilomyxoid astrocytomas, diffuse
astrocytomas, and pleomorphic xanthoastrocytomas, and grade III astrocytic
tumors are called anaplastic astrocytomas (Louis et al., 2007). Grade II and
Grade III astrocytic lesions are infiltratively aggressive, may progress to a higher
grade lesion, and are associated with a poor clinical outcome (Yan et al., 2009).
Glioblastomas, gliosarcomas, and giant cell glioblastomas are characterized as
WHO grade IV tumors (Louis et al., 2007). These high grade gliomas are highly
invasive and are associated with an extremely poor clinical prognosis (Yan et al.,
2009).

The clinical prognosis of glioma patients depends on several criteria,

amongst them are age of the patient, performance status (Karnofsky Performance
Scale Score), and grade of the lesion (Görke et al., 2010).

2

Glioblastoma

Glioblastoma (GBM) may arise de novo (primary GBM; represents about
90% of cases) or from less malignant precursor lesions (secondary GBM) (Ohgaki
and Kleihues, 2011). Primary GBM typically affects people that are older than 45
years of age, while secondary GBM occurs more frequently in individuals that are
younger than that (Furnari et al, 2007). As our understanding of the molecular
pathogenesis of GBM has evolved, it has become clearer that primary and
secondary GBM have very different genetic profiles, even though they appear
indistinguishable by histology (Ohgaki and Kleihues, 2011).
Approximately 9000 people in the United States are diagnosed with GBM
per annum (Reardon and Wen, 2006). Of all human tumors, GBM is the most
difficult neoplasm to treat (Chakravarti et al., 2001). Even with the refinement of
conventional treatment options for GBM patients, outcomes have only slightly
improved over the past few decades (Sathornsumetee et al., 2007). The overall
five year survival rate for GBM patients is 3.4% (Gonzalez and Gilbert, 2005), with
most patients succumbing to the disease within 14 months (Görke et al., 2010).
However, as we understand more about the molecular pathogenesis of GBM,
targeted therapies will likely revolutionize their treatment (Sathornsumetee et al.,
2007).

3

GBM Treatment

The current standard of care for newly diagnosed GBM patients is to
surgically remove as much of the lesion/lesions as possible, followed by
fractionated radiotherapy along with concurrent and adjuvant treatment with
temozolomide (TMZ) (Colman, et al., 2010; Stupp et al., 2005). TMZ is a DNA
alkylating agent that methylates DNA at the O6 position of guanine (Lassman and
Holland, 2007). This results in several nucleotide mismatches in complementary
DNA, leading to many unsuccessful post-replicative attempts at mismatch repair,
ultimately leading to apoptosis (D'Atri et al., 1998). One significant prognostic
indicator of a favorable response to TMZ treatment is the degree of methylation,
or epigenetic silencing, of the O6-methylguanine-DNA-methyltransferase (MGMT)
gene promoter (Colman et al., 2010; Weller et al., 2010). MGMT promoter
methylation is commonly found (40–57%) in GBM (Ohgaki and Kleihues, 2009).
MGMT is a DNA repair protein that restores O6-alkylated bases caused by
chemotherapy, thereby counteracting the effect of TMZ treatment (Krakstad and
Chekenya, 2010). In a large multi-center phase III trial that evaluated the use of
TMZ for the treatment of primary GBM with different MGMT promoter methylation
statuses, improved survival was reported for those patients whose tumors had
methylation of the MGMT promoter (Sulman and Aldape, 2011).
Over the past few decades we have only seen a marginal improvement in
progression-free and overall survival, and therefore pre-clinical researchers have
focused their attention on being able to understand the genetic pathobiology of
these

tumors

(Gonzalez

and

Gilbert,

4

2005).

Even

though

targeted

chemotherapeutic approaches are still in their infancy, they hold a promise of
being able to alter the course of this relentless disease (Furnari et al., 2007).
Currently there are many challenges that hinder the responsiveness of
GBMs to targeted and non-targeted chemotherapy. One of the major obstacles
limiting treatment effectiveness is that perhaps not all of the neoplastic cells are
completely removed during resection, which invariably results in tumor recurrence.
Additionally, progenitor cells present in the bulk of the tumor are inherently
resistant to radiotherapy, and go on to form recurrent lesions that resist further
treatment (Phillips et al., 2006). Adding to this complication, the brain is enveloped
in a protective blood brain barrier that limits the delivery of polar compounds to the
central nervous system that have large molecular weights, such as proteins
(Reardon and Wen, 2006). Additionally, chemotherapeutic agents are often
actively pumped out of the brain by efflux pumps (Fletcher et al., 2010). Even
when chemotherapeutic agents reach the lesion, the highly heterogenous genetic
profile of these neoplasms ensures that not all cells are effectively treated
(Reardon and Wen, 2006). With all these challenges, patient outcomes remain
highly variable (Sulman and Aldape, 2011). It is therefore clear that new agents
that more closely target the biology of the disease need to be developed in order
to improve on treatment options for this lethal disease.
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Genetic Aberrations of Primary and Secondary GBM

Although it is still unclear what the cell of origin is for primary and
secondary GBM (Furnari et al., 2007), it has been proposed that primary GBM
arises from glial progenitor cells that have accumulated distinct genetic alterations
(Ohgaki and Kleihues, 2011). These include epidermal growth factor receptor
(EGFR) amplification / mutations / rearrangement, tumor protein 53 (TP53)
mutations,

phosphatase

and

tensin

homolog

(PTEN)

mutations,

neurofibromatosis-1 (NF1) alterations, and loss of heterozygosity (LOH) of 10p
and 10q (Ohgaki and Kleihues, 2011). Other genetic alterations that occur in
primary

GBM

are

INK4a/ARF

mutations,

Cyclin

D1/3

amplification

or

overexpression, murine double minute 2/4 amplification or overexpression, and BCell CLL/Lymphoma 2 Like Protein overexpression (Furnari et al., 2007).
There is evidence to suggest that secondary GBM originates from
progenitor cells that acquire an isocitrate dehydrogenase 1/2 (IDH1/IDH2)
mutation (Yan et al., 2009). IDH1/2 mutations occur in the majority of WHO Grade
II diffuse astrocytomas, and the frequency of mutation does not increase with
tumor grade (Ohgaki and Kleihues, 2011). The mutation status of IDH1/2
correlates favorably with a better prognosis for GBM patients. Patients are
predicted to survive as long as 31 months if their tumors have an IDH1/2 mutation,
versus half that survival time for patients whose tumors do not have an IDH1/2
mutation (Yan et al., 2009). Later, is was also shown that an IDH1 mutation status
held a lot of predictive power in assessing improved patient survival after surgical
resection and radiotherapy, with the mean survival being 27.1 months versus 11.3

6

months for those patients whose tumors did not have an IDH1 mutation
(Nobusawa et al. 2009). Additionally, diffuse astrocytomas have mutations in
TP53, and anaplastic astrocytomas acquire LOH of 10q (Ohgaki and Kleihues,
2011).
Key genetic alterations that play important roles in the development of
primary and secondary GBM are represented in Figure 1.

Figure 1. Genetic aberrations associated with the development of primary
and secondary GBM. [mutation (mut), overexpression (OE); loss of heterozygosity
(LOH)].
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GBM Subtypes

Using high-throughput expression profiling techniques, GBM has been
further classified into various subtypes based on their gene expression profiles
(Phillips et al., 2006; Verhaak et al., 2010). The first of these studies by Phillips
and colleagues (2006) identified three GBM subclasses, with those being
mesenchymal, proneural, and proliferative. They reported that the proneural
subclass had a gene expression signature that displayed neuronal lineage
markers. Patients with these tumors tended to live longer than patients with
tumors expressing mesenchymal (angiogenic) or proliferative markers. Analysis
using array comparative genomic hybridization methodologies identified that both
the poor prognostic groups had gains or amplification of the EGFR, which was not
seen in the proneural GBM subtype. Remarkably, the two poor prognosis
subtypes also expressed elevated levels of neural stem cell markers compared
with proneural tumors. Their results also showed that if a patient’s initial lesion
displayed proneural or proliferative markers, then the recurrent tumors would shift
their gene expression signature to represent that of the mesenchymal subtype.
The recurrent tumors were frequently upregulated in YKL-40, CD44, STAT3 and
vimentin; all markers of the mesenchymal-angiogenic phenotype (Phillips et al.,
2006). Importantly, these studies have led to the identification of a set of genes,
representing both the proneural and mesenchymal GBM subtypes, which has
been developed into a clinical test, compatible with how samples are processed
following resection, which predicts patient outcome (Colman et al., 2010).
Furthermore, these multigenes are currently being used to stratify patients in a
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large multi-center Phase III clinical trial (RTOG 0825) that determines whether the
addition of bevacizumab (Avastin; anti-VEGF; anti-angiogenic) to standard care
regimens improves survival (http://clinicaltrials.gov; Sulman and Aldape, 2011).
The second high-throughput profiling study that I would like to mention
stratified GBM molecularly in terms of gene expression signatures into four major
subtypes; proneural, neural, classic, and mesenchymal, (Verhaak et al., 2010).
Patterns of mutation and DNA copy number alterations were also integrated into
their analyses. They reported that the proneural signature had PDGFRA/IDH1
genetic aberrations, while the classic and mesenchymal GBM subtypes contained
mainly EGFR and NF1 aberrations, respectively. EGFR amplification was found in
as many as 95% of classic GBM tumors, and in at least 29% of those classified as
being mesenchymal. Increased copy numbers for both the hepatocyte growth
factor receptor (c-Met) and EGFR were seen in >86% of all GBM subclasses,
except for those tumors classified as being proneural.
These groundbreaking reports may lead to the identification of prognostic
and predictive markers that correlate with treatment response. Better therapies
could then be explored, with the ultimate goal of eventually being able to
personalize medicine (Sulman and Aldape, 2011).
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Dysregulated Receptor Tyrosine Kinases in GBM

The Cancer Genome Atlas (TCGA) Network (The Cancer Genome Atlas
Research Network, 2008) performed a comprehensive analysis of aberrations that
occur in GBM. They reported that there are three major pathways with
components that have significant alterations, with those being the receptor driven
RAS / phosphitidylinositol 3-kinase (PI3K) (88%), the NF1 (87%), and the p53
(78%) pathways.
Receptor tyrosine kinases (RTKs) are often aberrantly overexpressed and
overactive in human cancer, including GBM, and therefore targeting RTK
dysregulation has become a key strategy for targeted therapy (Krakstad and
Chekenya, 2010). The increased activation of RTKs occurs through liganddependent and ligand-independent mechanisms (Li et al., 2007; Pillay et al.,
2009; Shinomiya et al., 2004). These include, amplification of RTK signaling by
their ligands (Shinomiya et al., 2004), constitutive activation of receptors by
missense mutations or multiple exon deletion (Pillay et al., 2009), and receptor
crosstalk with resultant activation (Eder et al., 2009). Increased RTK expression
and activation in cancer cells contributes significantly to hallmark malignancy
phenotypes, such as increased proliferation, survival, invasion, glycolysis, cell
growth, and angiogenesis (Figure 2; Bertotti et al., 2009; Frederick et al., 2000;
Pillay et al., 2009; Wong et al., 1992). Although Figure 2 provides an incomplete
picture of all possible cellular events that may occur in response to RTK
dysregulation, the main molecular players involved in PI3K and mitogen activated
protein kinase (MAPK) pathway activation are shown.
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Figure 2. Biological responses of PI3K and MAPK pathway dysregulation.

EGFR

The EGFR (also known as HER1 / ErbB1) belongs to a larger family of
ErbB receptors with tyrosine kinase activity (Ymer et al., 2011). Other members of
this commonly linked ancestral family include ErbB2 (HER2/neu), ErbB3 (HER3)
and ErbB4 (HER4) (Huang et al., 2009). These EGFR family members regulate
diverse cellular processes, such as proliferation, migration, survival, adhesion,
and differentiation, which are important in normal development, and if
dysregulated may contribute to the development of cancer (Yarden and
Sliwkowski, 2001). EGFR family members share common domain organization,
with those being an extracellular ligand binding domain, a transmembrane
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domain, and an intracellular domain. The intracellular domain consists of a
tyrosine kinase domain and a c-terminal tail with multiple tyrosine residues that
can be autophosphorylated following receptor dimerization and activation (Huang
et al., 2009). Canonically, the wild type (WT) EGFR may be activated by seven
different ligands (Schneider and Wolf, 2009); epidermal growth factor (EGF),
transforming growth factor-α (TGF-α), heparin-binding EGF-like growth factor (HBEGF), amphiregulin, betacellulin, epiregulin, and epigen (Villares et al., 2007).
Ligand binding is crucial for the EGFR to homodimerize, or to heterodimerize with
other ErbB family receptors, so that activation and autophosphoryation can occur
(Ymer et al., 2011). The preferred autophosphorylation site of the WT EGFR is
Y1173 (Schmidt et al., 2003), however others such as Y1068 and Y1148 are also
indicative of its tyrosine kinase activity (Huang et al., 2009). The tyrosine residue,
Y1045, is a c-Cbl binding site that serves to downregulate the receptor after it has
been stimulated with ligand and ubiquitinated (Grovdal et al., 2004). The Y845 site
of EGFR is phosphorylated by Src family non-receptor protein tyrosine kinases
following their activation by the EGFR (Yamamoto et al., 2006).

EGFR Alterations in GBM

EGFR is overexpressed in approximately 60% of primary GBM cases and
in less than 10% of patients with secondary GBMs (Ohgaki and Kleihues, 2007),
indicating that EGFR alterations occur predominantly in aggressive cases. Several
mechanisms may additionally account for aberrant EGFR signaling in GBM, with
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one being the upregulated autocrine expression of its ligands (Huang et al., 2009;
Ramnarain et al., 2006; Singh and Harris, 2005). Enhanced EGFR activation in
GBM may also be caused by amplification or mutation, which taken together is
found in as many as 45% of all GBMs (The Cancer Genome Atlas Research
Network, 2008). Almost every classic GBM has focal amplification of the EGFR,
with the mesenchymal, neural, and proneural tumors amplifying the EGFR at
29%, 67%, and 17%, respectively (Verhaak et al., 2010). EGFR mutations are
also a frequent occurrence in GBM and are found in about a third of all tumors
belonging to the classic GBM subclass, and in many of the proneural, neural and
mesenchymal tumors (Verhaak et al., 2010).

Various point mutations in the

extracellular domain of the EGFR account for some of these aberrations (Lee et
al., 2006). During the amplification process, the EGFR gene is often rearranged,
which may also result in transcripts with large deletions (Cavenee, 2002). The
most common rearrangement of the EGFR gene is an in-frame 2-7 exon deletion
within the extracellular domain, and is known as ΔEGFR (de2–7 EGFR, EGFRvIII,
or EGFR*) (Ohgaki and Kleihues, 2007).

ΔEGFR

The in-frame 801bp deletion of the ∆EGFR gene results in a truncated
protein unable to bind its cognate ligands (Schmidt et al., 2003). Despite this, the
∆EGGR signals constitutively at a low-level, thereby successfully allowing it to
evade signals regulating internalization and downregulation (Huang et al., 1997;
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Hwang et al., 2011). This is in contrast with ligand-stimulated WT EGFR that is
rapidly attenuated following acute stimulation with ligand (Schmidt et al., 2003).
One of the primary reasons for the low signal intensity of the ∆EGFR is due to
inefficient dimerization (Hwang et al., 2011; Ymer et al., 2011). However, its
constitutive signal leads to increased survival of GBM cells in vivo, by augmenting
mitogenic effects and reducing apoptotic rates (Nagane et al., 1996). Interestingly,
when ∆EGFR is used to transform INK4A/Arf depleted astrocytes and neural stem
cells, high grade lesions are orthotopically and subcutaneously produced when
injected into nude mice (Bachoo et al., 2002), raising the possibility that it may be
one important initiating event in tumor development. Not only is ∆EGFR most
likely an important factor in gliomagenesis, but the tumorigenic potential of glioma
cells in vivo are significantly enhanced by ∆EGFR expression when compared
with those xenografts expressing the WT EGFR (Cavenee, 2002; Huang et al.,
1997; Nishikawa et al., 1994).

It has also been shown that cells expressing

∆EGFR are inherently recalcitrant to both radiation (Lammering et al., 2004) and
chemotherapy (Nagane et al., 1998). ∆EGFR also activates the PI3K-Akt-mTOR
pathway to a greater degree than the Ras-Raf-MEK cascade, and recruits the
activity of STATs (STAT3 and STAT5b) for enhanced cellular proliferation,
viability, and transformation (Chumbalkar et al., 2011; de la Iglesia et al., 2008;
Huang et al., 2009). Not surprisingly, ∆EGFR expression has been strongly
associated with a poor survival prognosis for patients whose tumors amplify
EGFR (Heimberger et al., 2005; Shinojima et al., 2003), or express YKL-40
(Pelloski et al., 2007).
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∆EGFR in GBM

The ∆EGFR is not detected in normal tissues, and is therefore a cancer
specific mutant of the EGFR (Wikstrand et al., 1998). Several studies have shown
that the ∆EGFR is expressed in about 45-50% of GBMs that amplify the WT
EGFR (Pedersen et al., 2001; Shinojima et al., 2003; Wikstrand et al., 1998). In a
more recent study performed by the TCGA Network, the ∆EGFR deletion is mostly
found in the classic GBM subclass (23%), a subclass amplifying EGFR the most
compared with other GBM subclasses, and in 3% of proneural and mesenchymal
GBMs (Verhaak et al., 2010). However, the 200 GBMs analyzed in this study may
have had a negative selection bias towards the ∆EGFR, as necrotic tissue, which
is frequently found in high grade GBM (Li et al., 2009), was limited to 40% of each
sample (Verhaak et al., 2010). Most likely the ∆EGFR was not detected in as
many GBMs as previously reported, due to the patchy expression of ∆EGFR
(Wiesner et al., 2009) in only a small percentage of the total number of cells in a
GBM (Jungbluth et al., 2003).

Targeting EGFR / ∆EGFR in GBM

Given that the EGFR is highly dysregulated in GBM, it is surprising that
EGFR inhibitors, including tyrosine kinase inhibitors (TKIs) that also target the
∆EGFR, have not lived up to their clinical promise (Halatsch et al., 2006).
Resistance to anti-EGFR therapy has been partly attributed to signal
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compensation by other RTKs, or via their transactivation by EGFR and ∆EGFR,
leading to the persistent activation of redundant signaling pathways (Camp et al.,
2005; Pillay et al., 2009). It has therefore become critically important to identify
key players that mediate their signal and maintain their biological characteristics.

c-Met

c-Met is a RTK essential for normal physiological and developmental
programs, such as branching morphogenesis, wound repair, organ patterning,
and organ homeostasis (Birchmeier et al., 2003; Trusolino et al., 2010). It is also a
protein highly active in most cancers, regulating processes such as metastasis,
angiogenesis, proliferation, survival, and invasion (Bardelli et al., 1997; Birchmeier
et al., 2003; Sheth et al., 2008). c-Met is produced as a glycosylated 170 kDa
precursor protein that is cleaved by proteases into a 50 kDa α-chain and a 145
kDa β-chain, which are linked by disulphide bridges (Crepaldi et al., 1994). The βchain spans the membrane, having an intracellular tyrosine kinase domain and a
large extracellular domain, and the α-chain is located extracellularly (Ma et al.,
2003; Figure 3).
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Figure 3. c-Met structural domains, major tyrosine phosphorylation sites,
and binding partners.

The hepatocyte growth factor (HGF), c-Met’s only known activating
physiological ligand, binds c-Met in the sema (Gherardi et al., 2003) and IP3/IP4
domains (Trusolino et al., 2010). The sema domain, also found in semaphorins
and plexins (Trusolino et al., 2010), is equally important for receptor dimerization
(Kong-Beltran et al., 2004). c-Met’s intracellular region contains a juxtamembrane
domain, tyrosine kinase catalytic domain, and a multi-functional docking site. All
three intracellular domains contain tyrosine residues that are phosphorylated
upon ligand binding (Hov et al., 2004).
Phosphorylation of c-Met Y1003 has been shown to be important for Cblmediated ubiquitination and degradation following receptor internalization (Abella
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et al., 2005; Li et al., 2007). The c-Met signal may also be downregulated by
decorin, an extracellular small leucine-rich proteoglycan, within first few minutes
of their association (Goldoni et al., 2009). Attenuation of c-Met signaling by
disintegrin

and

metalloprotease-mediated

extracellular

domain

cleavage,

produces a soluble N-terminal fragment that is capable of sequestering HGF
present in the extracellular environment; a process known as shedding. This
‘decoy’ fragment may also interfere with c-Met dimerization, ultimately leading to
signal attenuation. The membrane-anchored cytoplasmic tail is proteolytically
cleaved

by

γ-secretase

and

then

degraded

(Foveau

et

al.,

2009).

Phosphorylation of Y1234 and Y1235 of c-Met, which are located in the kinase
domain, are required for full receptor activation (Bardelli et al., 1997). In the
absence of activating mutations, Y1235 is the first tyrosine residue in the
autophosphorylation (kinase) domain to be phosphorylated, which is then followed
by Y1234 phosphorylation (Chiara et al., 2003). Once this occurs, phosphorylation
at Y1349 and Y1356 in the COOH terminus links Src homology 2 domain
containing signaling adapters and transducers to the receptor for initiation of
signal transduction (Peruzzi and Bottaro, 2006). These adapter proteins and
signaling effectors (listed in Figure 2) signal primarily through the PI3K signaling
cascade, signal transducer and activator of transcription proteins (STATs), MAPK
pathways, and the nuclear factor-κβ inhibitor-α – nuclear factor-κβ complex
(Birchmeier et al., 2003; Trusolino et al., 2010).
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Amplification of the c-Met Signal

c-Met signal amplification may occur via its interaction with the α6β4
integrin at the plasma membrane, which acts as an additional docking platform for
signaling adapters and transducers (Bertotti et al., 2006). Another protein that
intensifies the c-Met signal at the cell surface is the v6 splice variant of CD44,
which is a cell adhesion molecule connecting the extracellular matrix to the
cellular actin cytoskeleton. The ternary structure produced by the interaction of cMet, CD44v6 and HGF activates c-Met, which in turn results in the activation of
Ras, a MAPK pathway signaling effector (Trusolino et al., 2010). Ligandindependent strengthening of the c-Met signal may also occur through
interactions with semaphorin receptors at the plasma membrane, such as is the
case with class B plexins and neuropilin (Knutsen and Vande Woude, 2008).
Recently it was shown that in non-small cell lung cancer (NSCLC) cases that
acquired resistance to EGFR inhibitors, c-Met became amplified and its signal
transduced via ERBB3 activation (Engelman et al., 2007). Additionally, c-Met
interacts with the RON receptor tyrosine kinase, which it shares a great deal of
sequence homology with, and with the EGFR (Gentile et al., 2008), which will be
expanded upon later.
The compartmentalization of c-Met signaling on endosomes has gained a
lot of attention lately. After c-Met is stimulated by ligand and internalized by
clathrin-mediated endocytosis, the c-Met signal sustains ERK activation at
peripheral early endosomes. Activated ERK then translocates to cell adhesion
sites at the plasma membrane, which is mediated by protein kinase Cε, where cell
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migration is initiated (Kermorgant et al., 2004). The delivery of c-Met along
microtubules to the perinuclear compartment allows for the rapid activation and
translocation of STAT3 into the nucleus (Kermorgant and Parker, 2008), which
most likely shields STAT3 from phosphatases that may attenuate its signal
(Trusolino et al., 2010). Recently, Joffre and colleagues (2011) showed that
active, cancer-specific, c-Met mutants accumulate on endosomes due to
enhanced rates of endocytosis and reduced receptor degradation. Additionally,
they showed that c-Met aggregation on endosomes activates Rac1, which
ultimately leads to increased cell migration. When they blocked endocytosis,
which did not affect c-Met activity, tumorigenicity and metastasis were reduced in
vivo. Therefore, compartmentalization of the c-Met signal may serve to enhance
tumorigenicity by temporally spacing preferential signaling partners.

The c-Met / HGF axis in GBM

In normal tissues, HGF that is secreted by mesenchymal cells activates cMet on epithelial cells in a paracrine manner (Gentile et al., 2008; Moriyama et al.,
1998; Wojcik et al., 2006). In cancer (Hung and Elliott, 2001; Hov et al., 2004;
Rahimi et al., 1996), including GBM, both receptor and ligand pair are often
coexpressed, which establishes a permissive microenvironment for sustained
oncogenic signaling through c-Met (Abounader et al., 2005).
In 1997, Nabeshima and colleagues used immunohistochemistry to
examine the expression of c-Met across increasing grades of astrocytic tumors.
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They found that c-Met protein expression was enhanced in GBM compared with
tumors that represented lower grades of glioma.

Similarly, HGF protein

expression increases with glioma grade (Kunkel et al., 2001).
In total, there have been three studies published that have examined the
coexpression of c-Met and HGF in GBM. The first study by George F. Vande
Woude’s

research

group

(Koochekpour

et

al.,

1997)

used

double

immunofluorescence staining to show that HGF and c-Met expression increased
with glioma grade. These authors also found that costaining of c-Met and HGF
was present in 13 out of 15 GBMs. Soon after their discovery, Moriyama and
colleagues (1998) analyzed HGF and c-Met messenger ribonucleic acid (mRNA)
expression in GBMs. They found that their mRNA expression increased with
astrocytic tumor grade, and that both c-Met and HGF were coexpressed in 6 of 15
GBMs. A subsequent study analyzed the mRNA expression of HGF and c-Met in
a subset of 43 GBM tumors using Affymetrix U133 arrays (Beroukhim et al.,
2007). They showed that c-Met and HGF, which are located on chromosome 7
(Beau-Faller et al., 2008), were mostly coexpressed in GBM samples with broad
gains of chromosome 7 (P < 0.06). Trisomy of chromosome 7 is frequently found
(70%) in GBMs (Piccirillo et al., 2009), indicating that this signaling axis plays a
pivotal role in this tumor.
Not surprisingly, tumorigenicity was significantly enhanced upon the
intracranial implantation of HGF-overexpressing GBM cells into mice (Laterra et
al., 1997). This degree of tumorigenicity was reversed through the use of
U1snRNA/ribozymes that targeted c-Met or HGF in established GBM xenografts
(Abounader et al., 1999; Abounader et al., 2002). Further, other investigators
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have shown that inhibition of c-Met’s activity in intracranial GBM xenografts
impairs tumor growth (Buchanan et al., 2009; Tseng et al., 2008). However, GBM
tumors that are not addicted to the c-Met / HGF axis, meaning that these
molecules are not highly expressed and signaling, are unresponsive to c-Met
inhibition (Martens et al., 2006). These studies have been further expanded to
provide evidence that high-level expression of c-Met correlates with a worse
survival prognosis for GBM patients, when compared with those GBM patients
whose tumors did not express c-Met (Kong et al., 2009).

Cross-talk between the EGFR / ∆EGFR and c-Met Pathways

A complex relationship exists between EGFR and c-Met signaling, where
HGF-mediated c-Met activation increases EGFR ligand expression (TGF-α and
HB-EGF), thereby aiding in EGFR dysregulation (Reznik et al., 2008). Once
EGFR is activated by TGF-α and HB-EGF, c-Met expression may be stimulated in
a HIF-1α hypoxia-independent manner (Xu et al., 2010).
Although c-Met is primarily activated by its ligand, HGF, the ligandindependent activation of c-Met is emerging as an important contributing factor to
aberrant c-Met signaling (Yamamoto et al., 2006). Transactivation of c-Met by the
EGFR in cancer cells was first described by Jo and colleagues (2000). They
showed that upon EGFR stimulation by TGF-α that c-Met was activated, which
could be reversed with TGF-α and EGFR antagonists. Since then, c-Met
activation by EGFR has been confirmed in various cancer cell lines (Bergström et
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al., 2000; Bonine-Summers et al., 2007; Fischer et al., 2004; Pai et al., 2003),
suggesting that the EGFR signals through c-Met. This interaction has been
reported to be by direct association (Agarwal et al., 2009), and potentially
unidirectional, until a recent study showed that amplified c-Met is capable of
transactivating the EGFR (Bachleitner-Hofmann et al., 2008).
By enriching for phosphotyrosine peptides, Huang and colleagues (2007)
used mass spectrometry to examine preferential signaling of ∆EGFR in U87 GBM
cells. They overexpressed titrated levels of ∆EGFR in U87, and asked which
specific signaling events were most strengthened by the ∆EGFR signal. They
discovered that Y1234 of c-Met, which is a good indicator of its overall activation
(Chiara et al., 2003), was steadily activated with increased expression of ∆EGFR.
This indicated that c-Met activation was downstream of ∆EGFR signaling, and that
c-Met activity could be regulated by ∆EGFR in GBM cells. Additionally, they found
that c-Met inhibition could circumvent ∆EGFR-mediated chemoresistance in U87
cells.
Recently, our laboratory examined signaling differences in GBM cells by
mass spectrometry after tyrosine enrichment when ∆EGFR, kinase-inactive
∆EGFR (∆EGFR-ki), or WT EGFR was expressed, and when WT EGFR was
stimulated with EGF, which showed that c-Met is a preferential target of the
∆EGFR even when compared with EGF-stimulated EGFR (Chumbalkar et al.,
2011). c-Met activation was also examined in U87 xenografts expressing either
WT EGFR, ∆EGFR, or ∆EGFR-ki, where it was found that c-Met activation was
enhanced in those tumors expressing ∆EGFR (Chumbalkar et al., 2011). Another
group suggested that the kinase activity of ∆EGFR, and not autophosphorylation,
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is necessary to coactivate c-Met in a ligand-independent manner in GBM cells
(Pillay et al., 2009). Furthermore, their finding that when using EGFR and HGF
antagonists in combination to treat ∆EGFR-expressing c-Met-/HGF-dependent
GBM xenografts that a significant reduction in tumor growth would occur
compared with either agent alone, suggests the clinical potential of combination
therapy (Pillay et al., 2009).

Regulation of c-Met and HGF Expression

Aside from chromosome 7 trisomy (Beroukhim et al., 2007), mechanisms
governing aberrant HGF regulation in GBM have not yet been identified.
Functional studies in other cancer cell lines have highlighted the importance of the
transcriptional induction of the HGF gene as a major cause of dysregulated
autocrine HGF circuitry (Hung and Elliott, 2001; Wojcik et al., 2006). HGF gene
transcription in human cells has been shown to be regulated in the proximal
promoter at a Stat3-binding element (-99/-91; TTACCGTAA) (Tomida and Saito,
2004). Similarly, in mouse mammary carcinoma cells a -95 STAT3 consensus site
in the HGF gene was linked to aberrant HGF expression, which promoted
transformation (Wojcik et al., 2006). STAT3 signaling is required for the
maintenance of the aggressive mesenchymal phenotype in GBM, and its
expression (Carro et al., 2010) or activity (Birner et al., 2010) is a negative
prognostic factor for GBM patients. More than 90% of GBM tumors have elevated
STAT3 activity (Rahaman et al., 2002), which has been found to be imperative for
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c-Met / HGF-mediated anchorage-independent growth and tumorigenicity in vivo
(Zhang et al., 2002). c-Met is capable of activating STAT3 directly or indirectly
(Birchmeier

et

al.,

2003),

and

once

activated,

it

homodimerizes,

or

heterodimerizes with other STAT family members, and translocates to the nucleus
where it controls gene expression by binding to promoter elements (Song et al.,
2003).
In the 5’ flanking region of the mouse HGF promoter, a Sp1 binding site (318 to -303) binds Sp1 and Sp3 transcription factors to regulate HGF expression
(Jiang et al., 1997). Later, p53 was also found to regulate the mouse HGF
promoter (Seol et al., 1999). HGF may also be regulated in the basal promoter
region (-4 to +3 from the transcription start site) by CCAAT/ enhancer-binding
protein β (C/EBPβ) / C/EBPς. Binding of C/EBPβ to the HGF promoter could be
induced by the action of several cytokines, such as IL6, IL-1, TNF-α, and TGF-α.
Later, Jiang and colleagues (2001) also found that the mouse HGF promoter
bound ligand-activated peroxisome proliferator-activated receptor γ at - 246 to 233 bp upstream from the HGF gene’s transcription start site.
c-Met overexpression in GBM occurs through amplification (4-20%; Mueller
et al., 1997; The Cancer Genome Atlas Research Network, 2008), rare missense
mutations (Moon et al., 2000), upregulation of its transcriptional activity
(Abounader and Laterra, 2009; Kong et al., 2009), chromosome 7 trisomy
(Beroukhim et al., 2007), and through HGF-mediated activation of the c-Met
receptor (Abounader et al., 2001). c-Met stimulation by HGF not only induces the
expression of c-Met in GBM cells, but it also does so in lung adenocarcinoma cells
(Boccaccio et al., 1994). Since positive regulatory loops have also been described
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for other receptors and their ligands (Caolo et al., 2010; Chen et al., 2010; Clark et
al., 1985; Reem et al., 1984), we hypothesized that the enhanced levels of
autocrine HGF expression in GBM may additionally hinge on the action of c-Met.
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CHAPTER 2

MATERIALS AND METHODS
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Cell Culture

The U87MG and LN18 human GBM cells were originally obtained from the
American Type Culture Collection, and cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM
glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin. GBM cell lines were
cultured under normal growth conditions; 7% CO2 and 37°C in a humidified
incubator. Dr. Zhimin Lu (The University of Texas M. D. Anderson Cancer Center)
generously provided us with Madin-Darby Canine Kidney (MDCK) cells. Human
Embryonic Kidney 293FT cells were a kind gift from Dr. Howard Colman (The
University of Utah). These cells were cultured under normal conditions in a
humidified chamber that delivered 5% CO2 at 37°C. To establish identity, U87 and
LN18 GBM cells were DNA fingerprinted using a polymerase chain reaction
(PCR)-based approach (GenomeLab Human Short Tandem Repeat Primer set
from Beckman Coulter) (Table 1).

Table
1.
Short
tandem repeat fingerprinting
of GBM cells. U87 and
LN18 cells were analyzed
for their specific marker
allele
content
for
comparative purposes and
identification.
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Antibodies

The following primary antibodies were purchased from Cell Signaling and
used at the indicated final concentration: anti-c-Met (1:1000), anti-pc-Met
(Y1234/Y1235) (1:1000); anti-EGFR (1:1250), anti-pEGFR (Y1173) (1:1000), antiSTAT3 (1:1000), and anti-pSTAT3 (Y705) (1:1000). We obtained the anti-HGF
primary antibody from R&D Systems; it was diluted to a final concentration of
1:1000 for western blot (WB) analysis. For actin detection on western blots, we
used an anti-β-actin conjugated to horseradish peroxidase (1:50000) that was
purchased from Sigma. Secondary antibodies that were used were as follows:
anti-mouse secondary antibody (1:3000; Fisher Scientific); anti-rabbit secondary
antibody (1:20000; Jackson Immunoresearch Laboratories); and an anti-goat
secondary antibody (1:3000; Santa Cruz). For HGF neutralization experiments,
we used the HGF primary antibody at a final concentration of 0.6 µg/ml.

Reagents

The recombinant human HGF that was used in our studies was obtained
from Chemicon. The c-Met kinase inhibitor, SU11274, and the EGFR kinase
inhibitor, AG1478, were purchased from Calbiochem. Actinomycin D was obtained
from Sigma-Aldrich. Hygromycin B, G418, and puromycin were obtained from
Fischer Scientific. WP1193 was a generous gift from Dr. Waldemar Priebe (The
University of Texas M. D. Anderson Cancer Center).
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shRNA Infection of GBM Cells

HEK 293FT cells were cultured to 50% confluence in 10 cm plates and
transfected with short hairpin ribonucleic acids (shRNAs) targeting c-Met (1 µg;
pLK0.1 backbone; Open Biosystems) or a non-targeting scrambled shRNA (1 µg;
pLK0.1 backbone, Addgene number 1864), and pCMV-dR8.2 dvpr (0.9 µg;
Addgene number 8455), and pCMV-VSVG (0.1 µg; (Addgene number 8454)
(kindly shared by Dr. Ta-Jen Liu, U.T. MD Anderson Cancer Center), with 6 µL
Fugene HD (Roche), according to the manufacturer’s instructions. After 48 h, the
viral supernatant was filter sterilized through a 0.45 µM syringe filter, and either
stored at -80° or applied to 50% confluent U87 GBM cells after the addition of
hexadimethrine bromide (8 µg/mL). After 3 h of infection, viral supernatant was
removed and fresh media added to the cells. After 48 h, cells were split and
selected with puromycin (1 µg/mL) for 6 days. Cloning by limiting dilution was
performed to obtain clonal populations of U87 sh-c-Met clones. Details of the cMet shRNA pLKO.1 hairpin sequences may be found in Table 2.
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Open Biosystems #
Strand

Sequence

Accession#

TRCN0000009850

sense

5’-CAGAATGTCATTCTACATGAG-3’

NM_001127500.1

sh-c-Met #A

antisense

5’-CTCATGTAGAATGACATTCTG-3’

NM_001127500.1

TRCN0000040047

sense

5’-GCCAGCCTGAATGATGACATT-3’

NM_001127500.1

Sh-c-Met #B

antisense

5’-AATGTCATCATTCAGGCTGGC-3’

NM_001127500.1

Label

Table 2. pLKO.1 c-Met shRNA targeting constructs. Sequence and
sequence identifying information of the c-Met shRNA targeting sequences.

Generation of Kinase-deficient c-Met Plasmids

An internal 2kb fragment was restricted out of pMSCV-wt c-Met (a
generous gift from Dr. Lisa Elferink, UTMB) with Apa1, and the Apa1 ends of the
pMSCV-wt c-Met plasmid ligated to generate a pMSCV-wt c-Met (∆Apa1) plasmid.
QuickChange site-directed mutagenesis (Stratagene) was performed to create the
pMSCV-c-Met Y1234 (∆Apa1) and pMSCV-c-Met Y1235 (∆Apa1) mutants;
primers that were used are listed in Table 3. Next, the gel-purified internal 2kb
fragment (generated as previously described) was ligated into the pMSCV-c-Met
Y1234 (∆Apa1) and pMSCV-c-Met Y1235 (∆Apa1) mutant expression vectors that
had been restricted with Apa1 to generate the pMSCV-c-Met Y1234 and pMSCVc-Met Y1235 plasmids.
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Mutation

Strand

Sequence

Accession#

sense

5’-GAGACATGTATGATAAAGAATTCTAT
AGTGTACACAACAAAAC-3’

NM_001127500.1

c-Met Y1234F
antisense

5’-GTTTTGTTGTGTACACTATAGAATTC
TTTATCATACATGTCTC-3’

NM_001127500.1

sense

5’- CATGTATGATAAAGAATACTTTAGTGT
ACACAACAAAACAGG-3’

NM_001127500.1

antisense

5’- CCTGTTTTGTTGTGTACACTAAAGTAT
TCTTTATCATACATG-3’

NM_001127500.1

c-Met Y1235F

Table 3. Primers used to generate kinase-deficient c-Met mutants.

Transfection and Retroviral Infection

A constitutively active STAT3 (STAT3-CA) in a pcDNA3.1/Hygro(+) vector
was kindly provided by Dr. Robert Arceci (Johns Hopkins, Baltimore, MD, USA)
(Ning et al., 2001). The constitutively active STAT3 contains Cys substitutions at
Ala662 and Asn664 (Bromberg et al., 1999). The pcDNA3.1/Hygro(+) empty
vector was a generous gift from Dr. Suyun Huang (MD Anderson Cancer Center).
STAT3-CA and empty vector were transfected into 50% confluent U87-∆EGFR
cells using Fugene HD (Roche), according to the manufacturer’s instructions.
After 48 h, the cells were split and selected using 50 μg/mL Hygromycin B.
10 μg pLRNL-∆EGFR (a generous gift from Dr. H-J Huang, UCSD),
pMSCV-puro empty vector, pMSCV-wt c-Met, pMSCV-c-Met P991S, pMSCV-cMet Y1003 (c-Met plasmids were kind gifts from Dr. Lisa Elferink, UTMB),
pMSCV-c-Met Y1234, and pMSCV-c-Met Y1235 was packaged into viral particles
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using 50% confluent GP2 cells, pCMV-VSVG (10 μg) and Lipofectamine 2000,
according to the manufacturer’s instructions (Invitrogen). After 48 hrs, viral
supernatant was collected and sterilized through a 0.45 μM filter syringe. Viral
supernatant was stored at -80°C for future use, or used to infect either 50%
confluent U87 or U87 ∆EGFR GBM cells in T25 flasks using 0.8 μg/mL
hexadimethrine bromide. After 3 h, the viral supernatant was removed and
complete media added to the cells. When the dishes were confluent, the cells
were split and selected using G418 (200 μg/mL) or puromycin (1 μg/mL)
according to the selection marker present on the expression plasmid.

Cell Lysate Preparation and Western Blotting

For most western blot analyses, cells were cultured in 10% serum prior to
collection. For all immunoprecipitation experiments, cells were cultured in serumfree conditions for 20 h. Cells were then either collected, washed with phosphate
buffered saline (PBS), and then scraped into ice-cold PBS. Pellets were gently
resuspended in RadioImmunoPrecipitation (RIPA) lysis buffer (50mM Tris HCl pH
7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium Deoxycholate, 0.1% SDS)

that

contained phosphatase inhibitors (Sigma-Aldrich Cocktail Inhibitors I and II) and
SigmaFAST protease inhibitor cocktail (Sigma-Aldrich), and then passed through
a 21-gauge needle 10 times. Lysis proceeded on ice for 30 min before the
supernatant was clarified from the cellular debris by centrifugation. Protein
concentration was estimated colorimetrically using the Pierce BCA Protein Assay
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Kit (Thermo Scientific), and lysates were stored at -20°C until further analysis. For
western blot analysis, 20/30 µg protein was separated on 4-12% Bis-Tris NuPage
gels (Invitrogen), except for HGF analysis where 150 ug of protein lysate was
used.

Immunoprecipitation Assays

Total lysates were incubated with primary antibodies overnight with gentle
rocking at 4°C. For the c-Met immunoprecipitation assay, an anti-c-Met antibody
from R&D Systems was used. Subsequently, Protein G PLUS-Agarose beads
from Santa Cruz bound the complexes. The beads were washed thrice using
RIPA buffer, and then washed twice with ice-cold PBS. Immunoprecipitated
proteins (500 μg) were resolved on 4-12% Bis-Tris NuPage gels, and analyzed
using immunoblotting/western techniques that have been described.

RNA Extraction and Quantitative Real-time PCR

All cells were cultured in complete media in 10-cm diameter dishes until
they reached 80% confluence. All cells were cultured under normal conditions.
Cells were washed twice with PBS and scraped into ice-cold PBS. mRNA was
extracted from the cell pellets using Qiagen’s RNeasy Mini Kit, and quantified
using a NanoDrop 2000 instrument. Reverse transcription was performed with
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Bio-Rad’s iScript cDNA Synthesis Kit. For the quantitative detection of transcripts,
quantitative real-time PCR (qRT-PCR) was performed using FastStart SYBR
Green Master reagent (Roche) with the primers that are detailed in Table 4.
Samples were analyzed in duplicate/triplicate and normalized to an internal β-2microglobulin control. All experiments were repeated three times.

Primer

Strand

Sequence

Accession#

sense

5’-CTCACACCCGCTGGGAGTAC-3’

NM_000601.4

antisense

5’-TCCTTGACCTTGGATGCATTC-3’

NM_000601.4

sense

5’-GATCCCCATGGCAGCAGTAAAGCAAG-3’

NM_138578.1

antisense

5’-CCCCATCCCGGAAGAGTTCATTCACT-3’

NM_138578.1

sense

5’-ATCCATCCGACATTGAAGTT-3’

NM_004048.2

antisense

5’-GGCAGGCATACTCATCTTTT-3’

NM_004048.2

HGF

BCL-XL

β-2Microglobulin

Table 4. qRT-PCR primer sequences. Sequence of primers used in qRTPCR experiments.

ELISA

Cells were cultured in T225 flasks until they reached 80% confluence,
washed twice in PBS, and cultured for 24 h in 40 mLs of serum-free media.
Conditioned media (CM) from duplicate samples were pooled, centrifuged for
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debris removal, and stored at -80°C until further analysis. Samples were
concentrated using an Amicon concentrator using a regenerated cellulose
ultrafiltration membrane with a 30,000 molecular weight cut off (Millipore). A 96well Nunc MaxiSorp plate was coated with 0.5 µg/mL mouse anti-human HGF
monoclonal antibody (R&D Systems) or isotype control antibody diluted in PBS.
Following an overnight incubation at room temperature (RT), wells were washed
in PBS containing 0.05% Tween 20 (PBST), blocked for 1 hour at RT in 50mM
Tris pH 8.0 containing 0.14 M NaCl, 1% BSA, and 0.05% Tween 20, and then
washed with PBST. The concentrated samples, and a HGF standard, were
serially diluted in Tris-buffered saline containing 0.1% BSA and 0.05% Tween 20
(pH 7.3), and then 100µL of each sample was applied to wells of the plate.
Additionally, in order to control for background noise of the assay, a media only
control was added to three wells of the plate. Following an overnight incubation at
4°C, wells were washed with PBST, and incubated for 2 hr at room temperature
with 100 µL goat anti-human HGF polyclonal antibody (0.5 µg/mL; R&D Systems).
After washing with PBST, 100 µL of HRP-conjugated bovine anti-goat IgG (40
ng/mL; Jackson ImmunoResearch Laboratories Inc.) was added per well, and
incubated for 1 hr at RT. Non-bound antibody was removed by washing with
PBST. For the detection of HGF, QuantaBlu™ Fluorogenic Peroxidase Substrate
(Thermo Fisher Scientific) was prepared according to the manufacturer’s
instructions, and 100 µL added per well. The reaction was terminated after 30 min
using QuantaBlu™ Stop Solution (Thermo Fisher Scientific), and the fluorescence
(Ex325/Em420) measured using a SpectraMax Gemini (Molecular Probes)
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fluorescent plate reader having SOFTmax Pro (v. 3.0) software. HGF ELISAs
were performed twice.

Luciferase Assays

The human HGF promoter construct pGL2-HGF-1029 was a kind gift from
Dr. Tomida, Saitama Cancer Center, Japan (Tomida and Saito, 2004). The
1029bp sequence of the 5’-flanking region of the HGF gene was cloned into
XhoI/HindIII sites of the luciferase reporter plasmid pGL2-basic (Promega).
Cells were plated in six-well plates (1x105) the day before transfection.
Fugene HD was used to transfect the HGF luciferase promoter constructs (1
µg/well), or the pGL2 empty vector (1 µg/well), along with the pSV-βGalactosidase Control Vector (10 ng), using 3 µL Fugene HD (Roche) per well.
After 48 h, lysates were prepared with the lysis buffer present in the Dual-Glo
Luciferase Assay System (Promega) and analyzed for their luciferase activity
according to the manufacturer’s instructions. β-galactosidase activity (Beta-Glo
Assay System; Promega) was also measured in the lysates with a luminometer
according to the manufacturer’s instructions. Transfection efficiency for each
sample was normalized by calculating the luciferase activity to that of βgalactosidase activity. A mean relative value was then calculated.
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Anchorage-independent Growth Assays

For colony formation, U87, U87 sh-c-Met #A2, U87 sh-c-Met #B2, U87 shcontrol ∆EGFR, U87 sh-c-Met #A2 ∆EGFR, and U87 sh-c-Met #B2 ∆EGFR cells
were seeded at 7.5 x 102 cells / well in media containing 0.5% low-melting
Agarose on a 0.7% low-melting agarose base in 24-well plates. U87 sh-control
pcDNA3.1, U87 sh-control STAT3-CA, U87 sh-c-Met #B2 pcDNA3.1, and U87 shc-Met #B2 STAT3-CA cells were plated at 1.5x103 cells / well in 12-well plates.
After 1 h, 0.25 mL of media was added to wells of the 24-well plates, and 0.5 mL
of media was added per well to the 12-well plates. Another aliquot of media was
added to wells of the plates after 7 days in culture. Cells were cultured at 37°C in
a humidified chamber receiving 7% CO 2. Colony numbers were counted after 14
days in culture using GelCount’s software and scanner. Additional experimental
details have been previously described (Kajiwara et al., 2008).

WST-1 Assays

7.5 x 102 cells were plated per well of a 96-well plate in triplicate and
cultured for 72 h at 37°C in a humidified chamber set to deliver 7% CO 2. The
WST-1 assay was performed according to the manufacturer’s specifications
(Roche).
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Intracranial Xenograft Studies

8-12 wk old nude (nu/nu) mice were stereotactically injected with 2 x 105
cells in 5 μL PBS into the right frontal lobe. Mice were maintained at The
University of Texas MD Anderson Cancer Center’s Isolation Facility. Mice were
euthanized when they started to show symptoms of neurological damage from the
tumor burden, including but not limited to seizures, lethargy and paralysis. All
animal experiments were performed on the same day. The maintenance and care
of mice were conducted in accordance with Laboratory Animal Resources
Commission standards under an approved protocol (100712131).

Mass Spectrometry

Cells were grown in large 15cm-diameter cell culture dishes to 80%
confluence and then serum-starved for 24 h. Proteins from two biological
replicates were extracted from the cells using urea lysis buffer (20 mM HEPES pH
8.0, 9 M urea, 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate, 1
mM b-glycerophosphate). After 10 minutes on ice, cells were sonicated using 3
pulses at 30 seconds each, with 2 minutes incubation on ice between pulses.
After centrifugation at 20 000g for 20 min, lysates were reduced with 4.5mM
dithiothreitol for 20 min at 60°C. Samples were then alkylated in the dark at room
temperature for 15 min using carboxo-amidomethylation that contained 10 mM
iodoacetamide. Lysates were tryptically digested overnight at room temperature in
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a solution of HEPES and trypsin TPCK solution (Worthington Biochemical) to final
concentrations of 20 mM and 10 μg/mL, respectively. Peptides were then desalted
with Sep-Pak C18 columns (Waters Corp) and freeze-dried. Peptides were
resuspended in an Immunnoaffinity Purification (IAP) buffer (50mM MOPS, pH
7.2, 10 mM sodium phosphate, 50 mM NaCl), prior to the addition of P-Tyr-100
mouse monoclonal antibody beads (Cell Signaling). Samples were rotated at 4°C
overnight, and the beads washed thrice with IAP buffer and water. Trifluoroacetic
acid (0.15%; TFA) was used to elute the bound peptides, which were then further
purified using ZipTip C18 (Millipore Corp).
After the peptides had been resuspended in acetonitrile (3%) containing
0.1% TFA, they were loaded onto Protein ID #2 chip (Agilent; 40 nL enrichment
column, 75 μm x 150 mm analytical column). LC-MS/MS analysis was performed
in duplicate with Agilent’s 6340 Ion trap System with electron transfer dissociation
(ETD) capability, where fragmentation alternated between collision induced
dissociation and ETD modes. Four peptides were chosen per scan that had at
least a double charge. Two biological repeats were performed. For specific run
conditions, we followed the protocol of Chumbalkar et al., 2011.

Peptide Identification and Quantification

Initially the MS/MS spectra were extracted using Bruker CompassXport
(http://www.bruker.com) which created *.mzxml files, which were later converted
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to *.mgf files using Trans-Proteomic Pipeline (Seattle Proteome Center;
http://www.proteomecenter.org/software.php). Database searches of the human
subset of Swiss-Prot database’s proteins was performed using Mascot search
engine version 2.3.02 (http://www.matrixscience.com). Manual inspection of the
spectra was performed to assign phosphorylation sites. Based on retention time,
Ideal-Q (Tsou et al., 2010) software aligned the runs. Next, the peak areas were
calculated manually for all identified phosphopeptides, and the data normalized to
the run’s total ion current. Then we calculated individual mean peak areas for the
phosphopeptides. For more detailed information, we followed the protocol of
Chumbalkar et al., 2011.

TCGA Analysis

Level 3 gene expression data (Agilent 244K Custom Gene Expression chip
platform; AgilentG4502A_07) was downloaded from the TCGA Data Portal
(http://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp) on 07/15/11 to examine HGF
and c-Met mRNA expression in 495 GBMs.

The downloaded data was

represented as log10 ratios to Universal Human Reference RNA (Stratagene).
Spearman correlation (two-tailed, 95% CI) calculated the Spearman correlation
coefficient between c-Met and HGF expression in GBM.

For GBM subtype

determination, ‘Verhaak determined’ data made use of the subtype calls that can
be found in the supplementary data from Verhaak et al., 2010. For ‘Calculated
Verhaak’ or ‘Calculated Phillips’ datasets, we downloaded the gene lists that were
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defined by the authors for the various GBM subtypes (Phillips et al., 2006;
Verhaak et al., 2010). For each tumor, expression values for genes that defined
each GBM subclass were averaged to derive a metagene score per each of the
four Verhaak GBM subtypes (mesenchymal, proneural, neural, and classical), and
for each of the three Phillips GBM subtypes (mesenchymal, proliferative, and
proneural).

Metagene scores were converted to z-scores (assume metagene

score normal distribution, and set all scores to mean = 0 and standard deviation =
1) so that metagene scores could be compared. A GBM subtype was then
assigned to a tumor based on the metagene score with the highest value. The use
of metagenes in statistics has previously been described by Colman et al., 2010.
Data validity was verified in an independent gene expression data set
(n=180)

from

(REMBRANDT;

the

REpository

for

Molecular

BRAin

http://caintegrator-info.nci.nih.gov/rembrandt)

Neoplasia
that

used

DaTa
the

Human Genome U133 Plus 2.0 Array; gene expression data normalized to pooled
normal brain expression. Data were processed using a robust multiarray average
(RMA) algorithm with quantile normalization, using R (R Development Core Team,
2009) and Bioconductor (Gentleman et al., 2004) and a custom CDF (Sandberg
and Larsson, 2007). GBM subtype calls were performed as was previously
described in the ‘Calculated Verhaak’ method.
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Statistical Analysis

GraphPad Prism 5.03 software was used to determine significance of most
experiments. Specific statistical tests are described in the figure legends. All ttests and the Spearman correlation test were two-tailed.
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CHAPTER 3

RESULTS

C-MET MODULATES HGF EXPRESSION, COLONY FORMATION,
AND TUMORIGENICITY OF GBM CELLS
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Coexpression of c-Met and HGF in GBM

There have been reports that c-Met and HGF mRNA are often coexpressed
in GBM (Beroukhim et al., 2007; Moriyama et al., 1998), prompting us to analyze
the wealth of new data now available in the TCGA database. The TCGA database
(http://tcga-data.nci.nih.gov/tcga/findArchives.htm) was established to generate a
comprehensive archive of various genetic aberrations that occur in cancer, with
their initial focus on GBM (Verhaak et al., 2010). The TCGA database catalogs
DNA, mRNA, microRNA and DNA methylation profiles of GBM tumors (Sulman
and Aldape, 2011; The Cancer Genome Atlas Research Network, 2008). We
analyzed the coexpression of c-Met and HGF in the TCGA expression data using
the Agilent (level 3; processed) platform. In total 495 GBM tumors were analyzed
for their c-Met and HGF expression. We found that c-Met and HGF mRNA
expression correlated significantly in GBM (Figure 4; Spearman correlation; r =
0.5199, P < 0.0001), suggesting that the two proteins are coregulated.
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Figure 4. HGF and c-Met mRNA expression correlates in GBM. TCGA
mRNA expression data for HGF and c-Met were correlated in 495 GBM tumors
using Spearman correlation (r = 0.5199; P<0.0001; linear regression is shown;
TCGA level 3 expression data for the Agilent platform was downloaded as log10
ratios to Universal Human Reference RNA; Dr. Brian Vaillant, Dr. Howard
Colman’s former post-doctoral fellow, performed this analysis).

c-Met Modulates HGF Expression

c-Met and HGF are both located on the same arm of chromosome 7 (7q31
and 7q21, respectively; Beau-Faller et al., 2008). Even though trisomy of
chromosome 7 is a frequent occurrence in GBM (Lopez-Gines et al., 2005;
Piccirillo et al., 2009), our data shows a broad dynamic range of expression for
HGF and c-Met that is not easily accounted for by the addition of a single gene
copy. One possible mechanism that may explain their coordinated regulation may
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be due to the formation of a positive regulatory loop. It has been shown previously
that c-Met’s expression can be induced by HGF stimulation (8 h) in GBM cells
(Abounader et al., 2001). We therefore hypothesized that HGF expression may
positively be modulated by its own receptor.
Immortalized human cancer cells have been used for many decades as
useful biological tools with which to expand our knowledge of cancer biology.
Certain tumor cells are largely reliant on specific oncogenes that they express for
the generation of prosurvival signals (Pillay et al., 2009). Cell lines that coexpress
HGF and c-Met are considered c-Met-dependent cell lines (Beroukhim et al.,
2007), and are dependent on this signaling axis for proliferation and survival
(Martens et al., 2006; Pillay et al., 2009). U87 is one such c-Met-dependent GBM
cell line (Pillay et al., 2009). Therefore, we confirmed that c-Met could be acutely
activated by recombinant human HGF (rhHGF) in U87 cells (Figure 5), and that
HGF was being secreted by this cell line (Figure 6). c-Met was activated
(Y1234/Y1235) within 5 minutes of HGF stimulation in U87 cells, with strongest
activity seen between 15 and 45 minutes of treatment (Figure 5). AKT
phosphorylation at S473 was used to assess PI3K pathway activation, which
occurred within 30 minutes of HGF stimulation.

47

Figure 5. c-Met is acutely activated by HGF in U87 cells. Western blots
measured c-Met activation (Y1234/Y1235), and p-AKT (S473), via HGF
stimulation (50 ng/mL) of U87 cells for the indicated amounts of time. EGF
stimulation (10 ng/mL) of U87 cells was used as a positive control. Vinculin was
used as a loading control.

Using ELISA, we did not detect HGF secretion from U251, a GBM cell line
known not to produce HGF (Beroukhim et al., 2007). Conversely, HGF secretion
was detected in conditioned media from U87 cells (Figure 6).
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Figure 6. HGF is secreted by U87 cells. ELISA quantification of HGF in CM
from U87 and U251 GBM cells. Cells were cultured in serum-free conditions for 24
h (triplicate serial dilutions analyzed above background; Dr. Kristen Hill, Dr. Lisa
Elferink’s former graduate student, UTMB, performed the analysis).

Based on these findings we used the U87 cell line to investigate the effect
of c-Met abrogation on the expression of HGF. We stably expressed lentiviral
short hairpin RNA (shRNA) constructs that targeted c-Met in U87 cells, and
established clonal populations from the two most effective shRNA constructs by
limiting dilution (data not shown). As measured by quantitative RT-PCR (qRTPCR), knockdown of c-Met decreased HGF expression at the mRNA level in U87
cells (Figure 7).
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Figure 7. HGF mRNA expression is dependent on c-Met expression. qRTPCR analysis of HGF mRNA expression in clonal populations of U87 cells that
expressed different c-Met shRNA targeting constructs. Cells were cultured in
media containing 10% FBS (** = P<0.01; Student’s t-test compared with shcontrol; n = 3±SEM; samples were analyzed at least in duplicate per experiment).

mRNA levels are not necessarily comparable to protein amounts within a
cell, therefore it was important for us to investigate what effect c-Met silencing
would have on HGF protein levels. We examined U87 c-Met knockdown cells
using western blotting techniques and confirmed that HGF protein levels
decreased with c-Met knockdown (Figure 8).
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Figure 8. HGF protein expression is dependent on c-Met expression.
Western blot analysis of HGF protein expression in clonal populations of U87 cells
that expressed different c-Met shRNA targeting constructs. Protein lysates were
obtained from cells that were cultured in media containing 10% FBS.

Given that HGF is a secreted protein that binds and activates the c-Met
receptor at the cell surface, we performed Enzyme-linked Immunosorbent Assays
(ELISAs) to analyze HGF amounts that were secreted into the CM from U87 cells
with c-Met knockdown. We found that HGF secretion was attenuated by c-Met
knockdown in U87 cells (Figure 9A). Western blot analysis revealed that levels of
secreted HGF were not proportional to the degree of c-Met knockdown (Figure
9B). This suggested that threshold levels of c-Met expression may modulate the
expression of HGF in this cell line. Cumulatively, our data revealed that the
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expression of c-Met is an important component necessary for the production and
secretion of HGF in U87 GBM cells.

Figure 9. HGF secretion decreases with c-Met knockdown in U87 cells. (A)
ELISA quantification of HGF in CM from U87 sh-c-Met knockdown clones that
represent two different shRNA targeting sequences, A and B (** = P<0.01; oneway ANOVA compared with U87 sh-control cells; Dunnett’s multiple comparison
test; triplicate serial dilutions above background analyzed per experiment; n = 2;
Dr. Kristen Hill, Dr. Lisa Elferink’s former graduate student, UTMB, performed
these analyses). Cells were cultured in serum-free conditions. (B) Western
analysis showing c-Met knockdown in cell lines that were represented in A. Cells
were cultured in media containing 10% FBS.

Interestingly, using bright field microscopy we observed that the cellular
morphology of U87 cells changed with silencing of c-Met (Figure 10). The U87
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parental or sh-control cells had the appearance of being scattered, spindleshaped, mesenchymal-like cells, whereas the U87 cells with c-Met knockdown
appeared epithelial-like with loss of the scattering phenotype. HGF, also known as
scatter factor (Birchmeier et al., 2003), typically leads to the dissociation and
dispersion of epithelial cells (Maulik et al., 2002). Given our data showing that the
expression of HGF, or scatter factor, is lost with c-Met knockdown (Figures 7-9), it
is tempting to speculate that the altered morphology observed with c-Met
knockdown may in part be due to decreased HGF expression in these cells.

Figure 10. Cellular morphology changes with c-Met knockdown in U87
cells. Bright field microscopy of U87, U87 sh-control, U87 sh-c-Met #A and U87
sh-c-Met #B polyclonal populations.
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We next examined whether the kinase function of c-Met was important for
this phenotypic change. We generated and overexpressed kinase-deficient c-Met
mutants (Y1234F and Y1235F), wt-c-Met, and oncogenic c-Met mutants [P991S
(Lee et al., 2000); Y1003F (Abella et al., 2005)], in U87 cells (Figure 11A). Bright
field microscopy revealed that the U87 cells expressing kinase-deficient mutants
lost their spindle, mesenchymal-like, appearance and were transformed into
cuboidal, epithelial-like, shaped cells (Figure 11B). These results suggest that
Y1234 and Y1235 of c-Met are necessary to maintain the mesenchymal-like
morphology of U87 GBM cells.

54

Figure 11. Cellular morphology alters with overexpression of kinaseimpaired c-Met mutants in U87 cells. (A) Western blot analysis of U87 cells that
overexpressed an empty vector control (pMSCV-puro), wt c-Met, c-Met P991S, cMet Y1003F, c-Met Y1234F, and Y1235F. (B) Bright field microscopy of all cell
lines represented in (A).
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Next, we asked whether the c-Met signal was required for HGF production.
To answer this question, we treated U87 cells with SU11274. This compound
selectively targets the c-Met receptor by a factor of 50 when compared with other
receptor tyrosine kinases (Peruzzi and Bottaro, 2006). The treatment of U87 GBM
cells with SU11274 decreased HGF mRNA (Figure 12A) and protein (Figure 12B)
amounts.

Figure 12. c-Met inhibition reduces HGF mRNA and protein amounts in
U87 cells. (A) HGF qRT-PCR of U87 cells treated with 10 µM SU11274 for 16h;
media contained 10% FBS (* = P<0.05; Student’s t-test compared with 0.1%
DMSO control; n = 4±SEM; at least duplicate samples per experiment). (B)
Western blot analysis of HGF and c-Met activity levels (Y1234/Y1235) in U87 cells
after 0.1% DMSO or 10 μM SU11274 treatment for 16h; media contained 10%
FBS.
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We wanted to determine if HGF expression would also be suppressed in a
cell line other than U87 when c-Met’s tyrosine kinase activity was inhibited. The
GBM cell line LN18 produces both c-Met and HGF, and is therefore considered cMet-dependent (Beroukhim et al., 2007). We treated LN18 cells with SU11274 to
inhibit c-Met activity, and analyzed HGF content by qRT-PCR and by western
analysis. We found that LN18 cells responded analogously to that of U87 cells,
where HGF mRNA (Figure 13A) and protein (Figure 13B) amounts decreased with
c-Met inhibition.

Figure 13. HGF mRNA expression and protein levels decrease with c-Met
knockdown in LN18 cells. (A) HGF qRT-PCR of LN18 cells treated with 10 µM
SU11274 for 16h; media contained 10% FBS (** = P<0.01; Student’s t-test
compared with 0.1% DMSO control; n = 4±SEM; at least duplicate samples per
experiment). (B) Western blot analysis of HGF and c-Met activity levels
(Y1234/Y1235) in LN18 cells after 0.1% DMSO or 10 μM SU11274 treatment for
16h; media contained 10% FBS.
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Taken together, our results suggest that the coregulation of HGF and c-Met
occurs primarily at the mRNA level, and that the activity of c-Met is required for
HGF expression in GBM cells.

c-Met is Required for Anchorage-independent Growth of U87
Cells

Next, we characterized the biological implications of shRNA-mediated
silencing of c-Met in U87 cells. Initially, we started our investigations by
performing anchorage-independent growth assays, since it is a quick and simple
method to perform, yet models some important aspects of tumorigenicity in vivo,
such as cancer cell proliferation without firm attachment. We found that the
number of colonies (Figure 14A), and the size of the colonies (Figure 14B),
decreased significantly with reduced c-Met expression in U87 cells.
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Figure 14. Anchorage-independent growth of U87 cells with c-Met
knockdown. (A) Colony formation assays determined the number of colonies
produced by U87 sh-control cells when compared with U87 shRNA-c-Met clones
(different targeting constructs) after growth for 14 days (* = P<0.05; Student’s ttest; n = 3±SEM; at least triplicate samples per experiment). (B) Representative
images of colony formation on day 14.

To understand the mechanisms that may contribute to the decreased
anchorage-independent growth of U87 sh-c-Met cells, we performed WST-1
assays that measured the metabolic activity of viable cells. Even though all of the
cell lines were plated on the same day using equal cell numbers, and grown under
the same conditions, the metabolic activities of the U87 sh-c-Met clones were less
than that observed in the U87 sh-control cells after 3 days of growth (Figure 15A).
Therefore, the total number of viable cells may have decreased over time with cMet knockdown when compared with the scrambled sh-control cell line.
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Although it’s not definitive proof of apoptosis, altered BCL-XL expression
levels suggest that changes in cell viability have occurred (Boise et al., 1993,
Nagane et al., 1996). Using qRT-PCR, we showed that BCL-XL expression
decreased with SU11274 treatment of U87 cells (Figure 15B).

Figure 15. c-Met suppression alters biological characteristics of U87 cells.
(A) WST-1 assays measured the metabolic activities of U87 sh-control cells, and
U87 sh-c-Met clones (different c-Met sh-RNA targeting constructs) after 72 h in
culture (± SEM); media contained 10% FBS (B) BCL-XL qRT-PCR of U87 cells
treated with 0.1% DMSO or 10 µM SU11274 for 16h (± SEM); media contained
10% FBS.

Taken together, the decrease in anchorage-independent growth of U87 shc-Met cells may be due to increased cell death. However, in order to support this
conclusion, additional experiments should be performed that would measure the
degree of apoptosis directly.
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Silencing c-Met Suppresses the Tumorigenicity of Intracranial
GBM Xenografts

We examined the tumorigenicity of U87 cells with c-Met knockdown in vivo
by measuring the survival of nude mice that had been intracranially injected with
these cells (Figure 16). The median survival of mice in the U87 sh-control group
was 16 days. After 65 days, we sacrificed the mice in the U87 sh-c-Met groups
since they did not show any neurological symptoms of tumor burden. We
confirmed the absence of tumors in two mouse brains per c-Met knockdown cell
line tested by microscopic examination of H&E stained brain sections.

Figure
16.
c-Met
silencing
decreases
the
tumorigenicity
of
U87
xenografts. Nude mice were
injected intracranially with
2x105 U87 sh-control or
2x105 U87 sh-c-Met clonal
cells and their survival was
documented over 65 days.
The median survival for each
group of mice and the
significant
differences
between them are shown
(Log-rank test; P<0.0001;
U87 sh-control versus U87
sh-c-Met clones).
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Taken together, our data suggest that the expression of c-Met is an
important component needed to maintain anchorage-independent growth and
tumorigenicity of U87 GBM cells.
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CHAPTER 4

RESULTS

∆EGFR REGULATES HGF EXPRESSION VIA C-MET ACTIVATION
AND REQUIRES C-MET FOR ONCOGENICITY
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∆EGFR Induces the Expression of HGF via c-Met Activation

Using an open mass spectrometry-based approach to examining the
∆EGFR signal in GBM cells, our laboratory (Chumbalkar et al., 2011), and an
independent group of investigators (Huang et al., 2007), found that the intensity of
the c-Met phosphopeptide Y1234 increased in response to the ∆EGFR signal in
GBM cells. Since the activity of c-Met is an important component necessary for
the production of HGF in c-Met-dependent GBM cells, we asked whether ∆EGFR
could increase HGF expression via c-Met activation. Using qRT-PCR, we found
that HGF mRNA amounts tripled with ∆EGFR expression in U87 cells (Figure 17).

Figure 17. ∆EGFR increases the mRNA expression of HGF. HGF mRNA
amounts were measured by qRT-PCR in U87 cells and in those that
overexpressed ∆EGFR (cells were cultured in DMEM media containing 10% FBS;
* = P<0.05; Student’s t-test; n = 3±SEM; samples were analyzed at least in
duplicate per experiment).
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We performed western blot analysis to confirm that the protein expression
of HGF increased with ∆EGFR expression (Figure 18). To confirm that increased
HGF

expression

correlates

with

enhanced

c-Met

signaling,

we

immunoprecipitated c-Met and performed western blot analysis. As shown in
Figure 18, c-Met activity was enhanced in the presence of constitutively active
∆EGFR. It was necessary to immunoprecipitate c-Met due to a strong crossreactivity of the pc-Met Y1234/Y1235 antibody with phosphorylated ∆EGFR; c-Met
and ∆EGFR are approximately the same size when analyzed by western blot.

Figure 18. ∆EGFR increases the protein expression of HGF. Western blots
measured HGF protein expression and p-c-Met (Y1234/Y1235) amounts after cMet was immunoprecipitated from lysates that were prepared from U87 and U87
∆EGFR cells. Cells were cultured for 20 h in media containing 1% serum.

Madin-Darby Canine Kidney (MDCK) cells are acutely sensitive to HGF
stimulation, and respond rapidly by eliciting c-Met-dependent biological programs
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(Cao et al., 2001; Christensen et al., 2003). Therefore, we used MDCK cells to
determine if HGF was being secreted from U87 cells that expressed ∆EGFR, and
if the secreted HGF was functional. Upon stimulation of MDCK cells with CM from
U87 ∆EGFR cells, we found that c-Met was acutely activated (Y1234/Y1235) in a
time-dependent manner (Figure 19). This level of c-Met activation was also
observed when MDCK cells were acutely stimulated with rhHGF. In order to prove
that HGF from U87 ∆EGFR CM was responsible for c-Met activation in MDCK
cells, we pre-neutralized HGF in an aliquot of the CM with an anti-HGF antibody.
This resulted in attenuation of the c-Met signal in MDCK cells when compared
with the signal generated by rhHGF stimulation or with untreated U87 ∆EGFR CM.
These data suggested that HGF was being secreted by U87 ∆EGFR cells, and
that the secreted HGF was functional.

Figure 19. Functional HGF is secreted by ∆EGFR-expressing GBM cells.
CM from U87 ∆EGFR cells was transferred to MDCK cells for the indicated
amounts of time (min). c-Met activation was detected by western blot. MDCK
cells were also stimulated for 15 min with rhHGF (50 ng/mL), or media (-), or with
CM that had been pre-neutralized for 2 h with an anti-HGF antibody. Cells were
cultured in media containing 1% FBS.
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Inhibition of ∆EGFR suppresses HGF expression

The kinase-dependent function of the ∆EGFR is responsible for enhanced
c-Met activation in GBM cells (Pillay et al., 2009). We have shown that c-Met is
responsive to the ∆EGFR signal (Figure 18; Chumbalkar et al., 2011), and that
HGF production increases with ∆EGFR overexpression (Figures 17-18).
Therefore, we tested the hypothesis that ∆EGFR’s kinase activity regulates HGF
expression. We inhibited the kinase activity of ∆EGFR with AG1478, a specific
EGFR TKI that preferentially antagonizes the ∆EGFR (Huang et al., 2007), and
analyzed HGF mRNA expression by qRT-PCR. This analysis revealed that HGF
mRNA amounts decreased with inhibition of the ∆EGFR signal (Figure 20). As
expected, HGF mRNA expression also decreased with SU11274 treatment of U87
∆EGFR cells. Treatment of U87 ∆EGFR cells with either SU11274 or AG1478
suppressed the expression of HGF to a similar extent. The dual inhibition of U87
∆EGFR cells with SU11274 and AG1478 did not result in greater attenuation of
HGF mRNA expression to that of either agent alone. These results suggest that
c-Met and ∆EGFR regulates HGF mRNA expression through the same pathway.
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Figure 20. HGF mRNA expression decreases with inhibition of ∆EGFR.
HGF mRNA amounts were measured by qRT-PCR of U87 ∆EGFR cells that were
either untreated, or treated with 0.1% DMSO, 10 µM AG1478, 10 µM SU11274, or
with a combination of 10 µM AG1478 and 10 µM SU11274. Cells were treated for
16 h in media containing 10% FBS (** = P<0.01; Student’s t-test when compared
with the DMSO-treated control; n = 3±SEM; samples were analyzed at least in
duplicate per experiment).

We performed western blot analysis in order to confirm that the treatment
of U87 ∆EGFR cells with SU11274 and AG1478 effectively inhibited the kinase
activities of c-Met and ∆EGFR, as well as the protein expression of HGF.
Surprisingly, AG1478 treatment of U87 ∆EGFR cells did not attenuate HGF
protein expression and c-Met phosphorylation (Y1234/Y1235) to the same extent
as

SU11274

(Figure

21).

The

inhibitor-dependent

decrease

in

c-Met

phosphorylation did however correlate with the amount of HGF that was being
produced at the protein level. Given that HGF mRNA and protein amounts are not
inhibited to the same extent following the treatment of U87 ∆EGFR cells with
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AG1478 (Figure 20 and Figure 21), our results suggest that HGF may also be
post-transcriptionally or post-translationally regulated in U87 ∆EGFR-expressing
cells. However, our data provide solid support for the existence of a positive feedforward relationship between the degree of c-Met activation and the level of HGF
protein expression.

Figure 21. HGF protein
expression is attenuated with
inhibition of ∆EGFR. HGF, pc-Met
(Y1234/Y1235),
and
pEGFR
(Y1173) levels were detected by
western blot analysis of U87
∆EGFR cells that were either
untreated or were treated with
0.1% DMSO, 10 µM AG1478, 10
µM SU11274, or a combination of
10 µM AG1478 and 10 µM
SU11274. pc-Met (Y1234/Y1235)
amounts were detected by western
blot
following
c-Met
immunoprecipitation. Cells were
treated for 16 h in media
containing 10% FBS.

c-Met is Required by ∆EGFR for HGF Production, AnchorageIndependent Growth, and Tumorigenicity of GBM Cells

We then asked whether HGF expression could be maintained by ∆EGFR in
the absence of c-Met. To answer this question, we overexpressed ∆EGFR in U87
sh-c-Met clones and examined HGF mRNA by qRT-PCR. We found that ∆EGFR

69

did not sustain HGF production when c-Met levels were silenced (Figure 22A).
HGF protein levels were then evaluated in U87 ∆EGFR sh-c-Met cells by western
blot analysis, and we found that the protein expression of HGF was attenuated
with c-Met knockdown in these cells (Figure 22B). As with previous experiments
where U87 cells were engineered to overexpress ∆EGFR (Figure 20 and Figure
21), there appears to be an uncoupling in regulation of HGF at the mRNA and
protein levels. Therefore, these data suggest that HGF may additionally be
controlled post-transcriptionally or post-translationally by the ∆EGFR signal.
Cumulatively, our findings suggest that ∆EGFR requires the presence of c-Met to
maintain enhanced levels of HGF expression in U87 cells.

Figure 22. c-Met is required by ∆EGFR to maintain HGF expression. (A)
HGF mRNA amounts were measure by qRT-PCR in U87 sh-c-Met clonal
populations (different c-Met shRNAs) that expressed ∆EGFR. Cells were cultured
in media containing 10% FBS (* = P<0.05; *** = P<0.001; Student’s t-test; n = 3 ±
SEM; samples were analyzed at least in duplicate per experiment). (B) HGF
protein levels were measured by western blot analysis in all cells detailed in (A).
Cells were cultured in media containing 10% FBS.
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We determined whether ΔEGFR was capable of overcoming the
suppression in anchorage-independent growth that we have previously seen with
c-Met knockdown in U87 cells (Figure 14). Our results indicated that ∆EGFR
required c-Met to exert its stimulation of anchorage-independent growth of U87
cells, as it was unable to rescue the loss in colony formation of U87 cells with cMet knockdown (Figure 23A). Even though the number of colonies for the U87 cell
line were comparable to the number of colonies of the U87 ΔEGFR cell line
(Figure 14A and Figure 23A), by visual examination we found that the colonies
produced by the latter cell line were far larger in diameter and volume compared
with the growth of parental cells (Figure 14B, and Figure 23B).

Figure 23. In vitro colony formation of U87 ΔEGFR-expressing cells with cMet knockdown. (A) Anchorage-independent growth assays determined the
number of U87 sh-control ΔEGFR colonies compared with U87 sh-c-Met #A2
ΔEGFR and U87 sh-c-Met #B2 ΔEGFR colonies after 14 days growth (* = P<0.05;
** = P<0.01; Student’s t-test; n = 3±SEM; at least triplicate samples per
experiment). (B) Representative images of anchorage-independent growth of cell
lines described in (A) on day 14.
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In order to determine if the diminished anchorage-independent growth of
U87 sh-c-Met ΔEGFR cells may partly be due to changes in cell viability and BCLXL expression, we performed WST-1 and qRT-PCR assays, respectively (Figure
24A and Figure 24B). We found that with c-Met knockdown, U87 ΔEGFR cells
were unable to maintain a high level of metabolic activity (Figure 24A), and that
BCL-XL expression decreased with c-Met inhibition in these cells (Figure 24B).
These results indicated that the total number of cells, and BCL-XL expression,
decreased with c-Met suppression in U87 ΔEGFR cells. These data suggested
that c-Met plays an important role in the viability of U87 cells even when ΔEGFR
is expressed.

Figure 24. Biological properties of U87 ΔEGFR cells are altered with c-Met
knockdown. (A) WST-1 assays measured changes in metabolic activity (± SEM)
of U87 ΔEGFR cells with c-Met knockdown (U87 sh-c-Met #A2 ΔEGFR cells and
U87 sh-c-Met #B2 ΔEGFR cells) after 72 h growth in media containing 10% FBS
(B) qRT-PCR quantified BCL-XL mRNA expression (±SEM) in U87 ΔEGFR cells
that were treated with 0.1% DMSO or 10 µM SU11274 for 16h in media containing
10% FBS.
72

The ∆EGFR is a potent oncogene that confers enhanced tumorigenicity to
U87 cells in vivo (Huang et al., 1997; Nishikawa et al., 1994). Our data therefore
raised the question of whether ∆EGFR was capable of overcoming the reduced
tumorigenicity that we’ve found to be associated with c-Met knockdown in U87
cells (Figure 16). Hence, we measured the survival of nude mice that had been
intracranially injected with either U87 sh-c-Met cells overexpressing ∆EGFR, with
U87 sh-control cells, or with U87 sh-control cells that overexpressed ∆EGFR over
a period of 65 days (Figure 25).

Figure 25. c-Met is required by ∆EGFR to enhance the tumorigenicity of
U87 cells. Over a period of 65 days, survival curves were generated from mice
that had been intracranially injected with 2x105 U87 sh-control ± ΔEGFR, U87 shc-Met #A2 ΔEGFR, or with U87 sh-c-Met #B2 ΔEGFR cells (Log-rank test;
P<0.0001 when compared with the U87 sh-control group; median survival per
group of mice was recorded).
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Compared with the U87 sh-control group, ∆EGFR overexpression
significantly augmented the tumorigenicity of U87 cells in vivo as expected from
many prior studies. Surprisingly, mice that received U87 sh-c-Met (#A2 or #B2
clones) cells that overexpressed ∆EGFR did not become moribund within 65 days
of intracranial injection. The absence of tumors in these mice was verified in H&E
stained serial sections by visual examination under a microscope. Cumulatively,
these data suggest that c-Met is an important component necessary for the
maintenance of tumorigenicity of c-Met-dependent GBM cells, regardless of the
∆EGFR signal.
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CHAPTER 5

RESULTS

STAT3 PARTIALLY MODULATES HGF EXPRESSION IN
RESPONSE TO THE C-MET SIGNAL IN ∆EGFR-EXPRESSING
GBM CELLS
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STAT3 is a Key Node Regulating HGF Expression in Response to
the c-Met Signal

We used an unbiased shotgun phosphoproteomics-based approach to
further understand the signaling events that lead to changes in HGF expression
upon modification of the c-Met signal in U87 and U87 ΔEGFR cells. We chose to
enrich for phosphotyrosine peptides so as to provide an accurate snapshot of
signaling events that were initiated by c-Met and ΔEGFR. By doing this, we also
increased the probability of being able to detect all phosphotyrosine modifications
present on low-abundance proteins, and phosphotyrosine-related signaling events
occurring in a milieu of unphosphorylated, serine-phosphorylated, and threoninephosphorylated proteins (Macek et al., 2009). Specifically, after recovering
tyrosine-phosphorylated peptides from tryptically digested lysates of U87 shcontrol, U87 sh-control ∆EGFR, U87 sh-c-Met #B2, and U87 sh-c-Met #B2
∆EGFR cells, we performed LC-MS/MS (see Figure 26 for a schematic of the
methodology that was performed).
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Figure 26. Schematic of mass spectrometry experiments. Two biological
repeats per cell line (U87 sh-control, U87 sh-control ∆EGFR, U87 sh-c-Met #B2,
and U87 sh-c-Met #B2 ∆EGFR) were processed and analyzed in duplicate by
mass spectroscopy (Dr. Vaibhav Chumbalkar, Dr. Oliver Bögler’s former postdoctoral fellow, performed all mass spectrometry experiments).

An equal volume of lysate from each cell line that was processed for
PhosphoScan was analyzed by western to confirm their identity (Figure 27).
These data also showed that comparable amounts of protein, as assessed by
actin levels, were present in each sample within a biological replicate set.
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Figure 27. Confirmation of sample identities that were processed for
PhosphoScan analysis. Western blot analysis of lysates that were used in mass
spectrometry experiments.

We identified 112 peptides that were tyrosine-phosphorylated, which
corresponded with 82 proteins. Table 5 provides a complete list of all
phosphotyrosine-modified peptides that were identified in our screen.

Peptide
Index

Swissprot ID
(Human)

1157

m/z

Charge

Modification site (s)

ABI1

765.5856

3

TLEPVKPPTVPNDyMTSPAR

1233
651
1063
1288

ABI1
ABL2/ABL1
ACK1
ACK1

966.5225
506.6402
802.5335
764.2574

3
3
3
3

NTPyKTLEPVKPPTVPNDYMTSPAR
LMTGDTyTAHAGAK
KPTyDPVSEDQDPLSSDFKR
VSSTHyYLLPERPSYLER

954
542
1764
919

ACTN1
ACTS
ANKL2
ANXA2

370.8297
802.4712
760.7147
963.2993

3
3
2
2

sIVNyKPK
DLYANNVMSGGtTMyPGIADR
yVVDLYLNTPDK
LSLEGDHSTPPSAyGSVK

78

927

ANXA2

642.7831

3

LSLEGDHSTPPSAyGSVK

1653
1339
849
2216

ANXA2
BCAR1
CALR
CCNL2

771.2139
656.7297
908.7309
415.302

2
3
3
3

SYSPyDMLESIR
HLLAPGPQDIyDVPPVR
GLQTSQDARFyALSAsFEPFSNK
ERSRsyER

883
863
893
1338

CDK1
CDK2
CDK3
CILP2

673.6172
633.7101
634.1149
339.2904

2
2
2
3

IGEGtyGVVYK
IGEGTyGVVYK
IGEGTYGVVyK
VRAyANDK

524
695
1779
634
1359
1487
1942
1013

CML1
COF1
CSKI2
CSKP
DCBD2
DCBD2
DCBD2
DYH6

838.6844
624.6044
817.7112
821.7138
694.248
977.9353
1012.035
690.5724

3
3
3
3
3
3
3
3

LVNALSEDTGHSSyPSHRSFTK
HELQANCyEEVKDR
NTyNQTALDIVNQFTTSQASR
GSItFKIVPSyRTQSSSCER
ATGNQPPPLVGTyNTLLSR
AGKPGLPAPDELVyQVPQSTQEVSGAGR
EVTTVLQADSAEyAQPLVGGIVGTLHQR
LVMTCAAFITMNPGyAGR

873
728
1372
678

DYH7
DYR1A
EF1A1
EGFR

844.2557
576.1992
698.1473
645.9033

3
2
2
2

NMEKANSLYVIKLsEPDyVR
IYQyIQSR
EHALLAyTLGVK
GSTAENAEyLR

1347
1605
1608
2191

EGFR
ENOA
ENOA
ENOA

773.0428
943.5977
628.9258
1023.007

3
2
3
3

GSHQISLDNPDyQQDFFPK
AAVPSGASTGIyEALELR
AAVPSGASTGIyEALELR
SFIKDyPVVSIEDPFDQDDWGAWQK

1903
2304
1548
1198
1552
1624
770
771

ENOG
EVPL
FKBP4
GCYA3
GDE
GDE
GRLF1
GRLF1

772.2438
367.7344
763.0661
404.0985
547.7351
732.2042
1014.507
676.6196

3
3
2
3
3
2
2
3

AGyTEKIVIGMDVAASEFYR
SQYRDLLK
EKKLyANMFER
INVsPTTy]R
EAMsAyNSHEEGR
FsCDVAEGKyK
NEEENIySVPHDSTQGK
NEEENIySVPHDSTQGK

1890
808
842
841

GRLF1
GSK3A
GSK3A
GSK3A/GSK3B

1086.948
721.2467
454.7474
681.7287

3
2
3
2

SVSSSPWLPQDGFDPSDyAEPMDAVVKPR
GEPNVsyICSR
GEPNVSyICSR
GEPNVSyICSR

681
949
2200
642
2048
1737
2247
1046
1960
955
1083
1107

IMPG1
ITB1
ITIH2
ITSN1
K2C1B
LDHA
LDHA
LRCC1
LY75
M3K8
MK01
MK01

802.5516
652.7658
502.407
423.9775
708.8024
600.2064
885.3657
612.3049
730.6363
884.0403
742.2217
769.2481

3
2
3
3
3
2
3
3
2
3
3
3

LRVCQEAVWEAyRIFLDR
WDTGENPIyK
LGFyFQsEDIK
GWFPKsyVK
GRSGGGYGSGCGGGGGSyGGsGR
DQLIyNLLK
GyTsWAIGLSVADLAESIMKNLR
RDTDITSESDyGNRK
yLNNLYKIIPK
ADIySLGATLIHMQTGTPPWVKR
VADPDHDHTGFLTEYyVATR
VADPDHDHTGFLtEYyVATR
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1135

MK03

751.7668

3

IADPEHDHTGFLTEyVATR

1153
719
725
2217

MK03
MK14
MK14
MLL3

778.1629
525.9742
789.0988
727.2823

3
3
2
2

IADPEHDHTGFLtEyVATR
HTDDEMTGyVATR
HTDDEMTGyVATR
KEKLyEsQNR

1534
693
1830
1760

NP1L2
ODPAT
OR8J1
OSBL5

547.8437
585.316
867.6084
760.8906

3
3
3
3

yDEPILKLLTDIK
YHGHsMSDPGVSyR
MASVFYtLVIPMLNPLIySLR
LTRNLLLSGDNELyPLSPGK

704
736
802
809
1410
1411
1754
981

PAXI
PAXI
PAXI
PAXI
PRP4B
PRP4B
PRRC1
PTN11

703.5767
677.1365
539.0703
808.4905
840.0695
1259.978
612.3048
908.8163

3
3
3
2
3
2
3
2

FIHQQPQSSsPVyGSSAK
FIHQQPQSSSPVyGSSAK
VGEEEHVySFPNK
VGEEEHVySFPNK
LCDFGSASHVADNDITPyLVSR
LCDFGSASHVADNDITPyLVSR
QMIYsAARAIAGMyK
IQNTGDYyDLYGGEK

1666
1694
819
1629

PTPRA
PTPRA
PTRF
PUR8

995.5192
663.9271
500.7654
528.9814

2
3
3
3

VVQEYIDAFSDyANFK
VVQEYIDAFSDyANFK
KSFTPDHVVyAR
RAFIITGQtyTR

1365
741
1002
1076

RGPD3
RHG42
RIN1
S12A5

491.0598
667.865
948.6034
847.27

3
3
3
3

MGSGLNSFyDQR
LDTASSNGyQRPGSVVAAK
EKPAQDPLyDVPNASGGQAGGPQRPGR
GLSLSAARyALLRLEEGPPHtK

1328
801
1097
1419
730
1155
2337
895

SETB2
SHB
SHB
SHC1
SMC1B
SRC8
SSH1
STA13

386.8967
835.1677
627.6371
988.7607
602.6334
746.0805
915.7318
502.2786

3
2
3
2
2
3
3
3

KLPQFKyR
GESAGyMEPYEAQR
DKVTIADDySDPFDAK
ELFDDPSyVNVQNLDK
yQSLLEELK
GPVSGTEPEPVySMEAADYR
sCPNGMEDDAIFGILNKVKPSyK
FDQTTRRSPyR

1968
2345
1822
574

STAR9
STAT3
SYNE1
TEKT4

754.4364
861.73
839.7582
363.4678

3
3
2
3

GTVLSyCETLLEPECSsR
YCRPESQEHPEADPGSAAPyLK
AQyHLKIGSsEQR
yHQAFADR

810
2306
1163
1303
1320
2183
656
975
1206
869
906
947

TITIN
TITIN
TLN1
TLN1
TLN1
TLN1
TPP2
TYK2
UBP36
VIME
VIME
VIME

382.0819
404.9394
563.3869
639.8245
958.8162
885.3069
859.9542
534.3826
993.5783
755.2954
754.7248
668.077

3
3
2
3
2
3
3
3
3
2
2
2

VGGGEyIELK
EISTsAKyR
ALDyYMLR
TMQFEPSTMVyDACR
TMQFEPSTMVyDACR
AVSSAIAQLLGEVAQGNENyAGIAAR
IPKGAGPGCyLAGSLTLsKTELGK
LLAQAEGEPCyIR
VKCSVCKSVSDtYDPyLDVALEIR
SLYASSPGGVyATR
SLYASSPGGVyATR
LGDLyEEEMR

80

879

VINC

512.7556

2

SFLDSGyR

544
1325
925
1156

VP13D
ZN483
ZNF45
ZO2

428.6271
603.4999
383.5233
639.1482

3
2
3
3

ARDAVSytDK
AFGysASLTK
syLQVHLK
IEIAQKHPDIyAVPIK

Table 5. List of peptides with a phosphotyrosine modification identified by
mass spectrometry. Peptides identified as being tyrosine phosphorylated by
PhosphoScan analysis are listed along with their peptide modification(s), chargeto-mass ratio, charge, and assigned peptide identification number.

The mean abundance (signal intensity) of all phosphotyrosine-modified
peptides that were discovered by mass spectrometry in U87-sh-control, U87 sh-cMet #B2, U87 sh-control ∆EGFR, and in U87 sh-c-Met #B2 ∆EGFR cells are listed
in Table 6.

Mean Abundance
Swissprot ID
(Human)
ABI1
ABI1
ABL2/ABL1
ACK1
ACK1
ACTN1
ACTS
ANKL2
ANXA2
ANXA2
ANXA2
BCAR1
CALR
CCNL2
CDK1
CDK2
CDK3
CILP2
CML1

1390002.36
158052.85
388297.30
922657.35
429038.44
128379.18
617198.57
1774484.45
711053.25
4590724.40
1218735.63
338525.72

U87 sh-c-Met
#B2
557123.89
27027.32
101083.20
333189.57
144901.52
136078.11
369574.73
2445698.98
281965.01
1656585.32
297124.22
170291.96

U87 sh-control
ΔEGFR
1490703.14
182937.34
493929.28
745719.99
559607.14
124709.16
704295.28
1422771.92
696757.11
2190044.66
1007833.07
240378.32

856490.77
98213.39
357808.24
3574261.61

144311.67
104840.38
955824.69
8766808.98

1577667.45
54001.81
624606.45
6128642.02

352306.49
114658.33
3886702.79
18815182.68

3396418.72
198869.28
110263.22

8328703.27
104733.45
94791.65

6794913.38
157605.84
556951.74

10262738.33
326180.47
470237.14

U87 sh-control
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U87 sh-c-Met
#B2 ΔEGFR
401405.14
73016.99
153875.20
715348.00
560046.88
168452.27
656811.68
2501135.40
476815.75
3652219.54
812580.46
457820.48

COF1
CSKI2
CSKP
DCBD2
DCBD2
DCBD2
DYH6
DYH7
DYR1A
EF1A1
EGFR
EGFR
ENOA
ENOA
ENOA
ENOG
EVPL
FKBP4
GCYA3
GDE
GDE
GRLF1
GRLF1
GRLF1
GSK3A
GSK3A
GSK3A/GSK3B
IMPG1
ITB1
ITIH2
ITSN1
K2C1B
LDHA
LDHA
LRCC1
LY75
M3K8
MK01
MK01
MK03
MK03
MK14
MK14
MLL3
NP1L2
ODPAT
OR8J1
OSBL5
PAXI

86620.46

48305.97

104066.87

95410.82

721190.38
218776.87
425302.85
401805.37

176123.34
70649.60
367333.51
308981.38

1541311.73
216349.67
239285.34
311079.20

694879.63
74970.31
215799.23
620632.76

142033.39
560410.51
86817.34
8262429.11

100294.09
321770.58
62947.91
2437101.61

175640.41
265848.97
48393.49
9503113.33

262152.16
212790.97
21957.75
7099249.49

419470.06
48479.48
153667.34
591440.38
813145.43
163483.09
163908.51
110101.06

286270.09
31038.18
138807.68
263297.31
240266.06
77074.08
382148.71
17203.91

506843.26
54539.98
1613495.47
539507.44
1003193.55
184819.13
440202.16
190048.12

515893.50
58243.35
2332661.72
674096.10
517421.27
137985.92
370887.04
135678.82

186902.72
290009.12
751602.89
1086822.68

449656.21
419760.09
1237566.66
673636.30

146856.64
318321.48
714019.64
403062.21

414893.25
271937.53
1570468.93
832924.82

551726.17
3769455.06
647273.97
292438.80

127120.43
735348.48
264677.75
116195.30

578900.76
4058405.24
531222.95
406780.29

131611.28
3251988.54
453676.11
308156.27

1284481.07
58973570.27
48187.08
414073.39
213895.65
191846.80
1004608.92
178060.84

361673.58
18487522.61
18389.24
105515.75
551833.13
254251.42
428898.19
356635.60

2258000.97
68422426.76
54606.81
249640.44
168948.65
144069.95
819603.07
200782.47

1052806.79
51875222.35
61369.63
253044.23
1180317.74
99209.40
800675.38
276784.13

937046.05
891307.14
951036.24
222848.73

246653.48
1987929.83
704593.96
60605.74

1004697.90
510156.21
1688136.87
196627.13

334786.50
1177797.79
1091289.86
92722.08

6162581.65
982491.32
4030442.06
1556220.89
460716.59
421256.65
13577863.43
603266.04
46419.13
113892.36
217517.75
142911.89

3025377.73
2458393.65
2575478.19
1093051.82
147457.89
197804.34
7888312.09
1629862.91
50736.35
96435.46
1057819.60
74099.51

8683044.75
6949922.49
5685960.73
2897934.66
493933.75
595724.34
22925084.03
569777.91
260792.17
136819.70
556028.01
128332.51

4169461.99
4580568.60
4674193.25
2900633.59
243555.30
152649.85
11205540.01
1653791.99
136124.88
57195.30
183019.46
204732.17
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PAXI
PAXI
PAXI
PRP4B
PRP4B
PRRC1
PTN11
PTPRA
PTPRA
PTRF
PUR8
RGPD3
RHG42
RIN1
S12A5
SETB2
SHB
SHB
SHC1
SMC1B
SRC8
SSH1
STA13
STAR9
STAT3
SYNE1
TEKT4
TITIN
TITIN
TLN1
TLN1
TLN1
TLN1
TPP2
TYK2
UBP36
VIME
VIME
VIME
VINC
VP13D
ZN483
ZNF45
ZO2

3425913.02

717944.37

2163262.61

2984657.09

1481296.61
668854.90
62508210.09
970333.54

385555.40
170925.79
10700694.99
249949.54

986958.93
629594.94
38639222.94
542897.06

2019925.20
603031.16
42857360.56
933738.06

680073.39
353620.17
180804.24
328479.48

271494.39
484080.79
106987.14
519433.10

690468.92
355906.63
78080.90
363376.01

1118398.09
595519.07
205051.99
562648.10

265348.74
471549.51
268844.55
145980.20
1361034.49
68673.86
90142.09
479254.88

301795.53
112110.67
445067.02
26016.70
1129682.34
589706.43
200632.22
137621.34

622019.56
775696.15
265452.70
214772.27
1106079.43
135749.53
123086.89
280839.62

614181.95
208785.66
446122.77
154456.97
824274.14
132364.21
135194.12
169672.56

264818.99
119915.23
166241.83
516368.90

149017.29
113395.27
65420.99
409707.97

458824.90
449191.18
135669.71
503111.45

311520.14
925914.91
180261.30
496457.58

162164.28
362436.22
934283.08
529238.13

199662.87
58877.91
389216.91
296316.17

186439.31
717986.29
550970.60
668754.82

237512.98
222776.68
658491.40
302675.77

701296.76
155574.86
554417.65
85602.64
411342.53
473842.88
267913.94
803581.90

431172.62
22708.13
135557.02
118260.96
832645.65
172340.28
79250.33
206432.88

585429.11
106416.80
110192.85
234272.73
1269804.27
340899.78
248350.52
675670.12

505765.76
49106.18
295694.52
398067.72
829497.92
260559.94
248087.55
362316.34

133942.55
234589.59
46025.10
577122.99

44955.13
181405.55
426206.40
338176.91

429553.76
363538.63
101046.95
845643.65

169451.57
340488.76
34069.23
522585.07

737212.49
496835.10
916028.31
284079.75
329195.30
2017668.03
594539.30

165750.07
360392.85
237204.26
64221.07
423184.49
1894840.99
241264.93

455206.91
418098.89
751924.80
234289.97
301593.77
2362456.32
492106.00

318707.84
142685.35
419799.49
154684.58
537240.64
2744836.59
246486.65

Table 6. Mean abundance of all tyrosine-phosphorylated peptides that
were identified by mass spectrometry. Listed are average phosphotyrosine
intensities that were quantified for each peptide.
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Since HGF expression decreases with c-Met knockdown, we were
interested in determining which phosphotyrosine peptides changed the most in
response to the c-Met signal in U87 and U87 ∆EGFR cells. Therefore, we
determined which peptides showed the most significant decrease in tyrosine
phosphorylation with c-Met knockdown in U87 sh-control cells and in U87 shcontrol ∆EGFR cells (Table 7). Those identified to decrease significantly in their
tyrosine phosphorylation status with c-Met knockdown in U87 sh-control ∆EGFR
cells, also had significantly reduced phosphotyrosine levels with c-Met silenced in
U87 sh-control cells.

Table 7. Peptides showing a significant decrease in tyrosine
phosphorylation with c-Met knockdown. Listed are peptides that showed the most
significant decrease in intensity of their phosphotyrosine signal with c-Met
knockdown in U87 sh-control and in U87 sh-control ∆EGFR cells (P < 0.05 was
considered significant; Student’s t-test; n = 2; duplicate samples per experiment).
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Mass spectra [intensity versus m/z (mass-to-charge ratio) plot] for all
phosphotyrosine-modified peptides that were most significantly attenuated in
response to c-Met knockdown in U87 sh-control and U87 sh-control ∆EGFR cells
are provided in Figure 28-1 through Figure 28-20.

Figure 28-1. Mass spectrum of the abl interactor 1 (ABl1) Y198 peptide.
This
spectrum
shows
Y198
phosphorylation
[(R)NTPyKTLEPVKPPTVPNDYMTSPAR(L)]. Peptide Index: 1233.

Figure 28-2. Mass spectrum of the abl interactor 1 (ABl1) Y213 peptide.
This spectrum shows Y213 phosphorylation [(K)TLEPVKPPTVPNDyMTSPAR(L)].
Peptide Index: 1157.
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Figure 28-3. Mass spectrum of the annexin A2 (ANXA2) Y238 peptide.
This spectrum shows Y238 phosphorylation [(K)SYSPyDMLESIR(K)] . Peptide
Index: 1653.

Figure 28-4. Mass spectrum of the mitogen-activated protein kinase 14
(MK14) (MAPK14) Y182 peptide. This spectrum shows Y182 phosphorylation
[(R)HTDDEMTGyVATR(W)]. Peptide Index: 719.

Figure 28-5. Mass spectrum of the L-lactate dehydrogenase A (LDHA)
Y247 S249 peptide. This spectrum shows Y247 and S249 phosphorylation
[(K)GyTsWAIGLSVADLAESIMKNLR(R)]. Peptide Index: 2247.
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Figure 28-6. Mass spectrum of the glycogen synthase kinase 3 α/β
(GSK3A/B) Y279 S282 peptide. This spectrum shows Y279 and S282
phosphorylation [(R)GEPNVSyICsR(Y)]. Peptide Index: 808.

Figure 28-7. Mass spectrum of the enolase A (ENOA) (ENO1) Y44
peptide.
This
spectrum
shows
Y44
phosphorylation
[(R)AAVPSGASTGIyEALELR(D)]. Peptide Index: 1608.

Figure 28-8. Mass spectrum of the glycogen synthase kinase 3α/β
(GSK3A/B) Y279 peptide. This spectrum shows Y279 phosphorylation
[(R)GEPNVSyICSR(Y)]. Peptide Index: 841.
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Figure 28-9. Mass spectrum of the src homology 2 domain-containing
adapter protein B (SHB) Y268 peptide. This spectrum shows Y268
phosphorylation [(K)GESAGyMEPYEAQR(I)]. Peptide Index: 801.

Figure 28-10. Mass spectrum of the serine/threonine-protein kinase PRP4
homolog (PRP4B) Y849 peptide. This spectrum shows Y849 phosphorylation
[(K)LCDFGSASHVADNDITPyLVSR(F)]. Peptide Index: 1410.
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Figure 28-11. Mass spectrum of the StAR-related lipid transfer protein 13
(STA13) (STARD13) Y39 peptide. This spectrum and table provides data that
indicates Y39 phosphorylation [(R)FDQTTRRSPyR(M)]. Peptide Index: 895.

Figure 28-12. Mass spectrum of the Rho-GTPase-activating protein 42
(RHG42) Y792 peptide. This spectrum shows Y792 phosphorylation
[(R)LDTASSNGyQRPGSVVAAK(A)]. Peptide Index: 741.

89

Figure 28-13. Mass spectrum of the paxillin (PAXI) (PXN) Y88 peptide.
This spectrum shows Y88 phosphorylation [(R)FIHQQPQSSSPVyGSSAK(T)].
Peptide Index: 736.

Figure 28-14. Mass spectrum of the glucocorticoid receptor DNA binding
factor 1 (GRLF1) Y1105 peptide. This spectrum shows Y1105 phosphorylation
[(R)NEEENIySVPHDSTQGK(I). Peptide Index: 770].

Figure 28-15. Mass spectrum of activated CDC42 kinase (ACK1) (TNK2)
Y518
peptide.
This
spectrum
shows
Y518
phosphorylation
[(K)KPTyDPVSEDQDPLSSDFKR(L)]. Peptide Index: 1063.
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Figure 28-16. Mass spectrum of the mitogen-activated protein kinase 1
(MK01) (MAPK1) Y185 peptide. This spectrum shows Y185 phosphorylation
[(R)VADPDHDHTGFLTEyVATR(W)]. Peptide Index: 1083.

Figure 28-17. Mass spectrum of the vinculin (VINC) Y822 peptide. This
spectrum shows Y822 phosphorylation [(K)SFLDSGyR(I)]. Peptide Index: 879.

Figure 28-18. Mass spectrum of the glucocorticoid receptor DNA-binding
factor 1 (GRLF1) Y1087 peptide. This spectrum shows Y1087 phosphorylation
[(K)SVSSSPWLPQDGFDPSDyAEPMDAVVKPR(N)]. Peptide Index: 1890.
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Figure 28-19. Mass spectrum of the vimentin (VIME) (VIM) Y61 peptide.
This spectrum shows Y61 phosphorylation [(R)SLYASSPGGVyATR(S)]. Peptide
Index: 906.

Figure 28-20. Mass spectrum of the Vimentin (VIME) (VIM) Y150 peptide.
This spectrum and table provides information that shows Y150 phosphorylation
[(R)LGDLyEEEMR(E)]. Peptide Index: 947.

We used Ingenuity Pathway Analysis (IPA; http://www.ingenuity.com) to
determine which c-Met-dependent signaling pathways are responsible for
decreased HGF expression. To do this, we used IPA software to connect known

92

modulators of HGF expression (Ingenuity Knowledge Base) with all of the
peptides that were identified in Table 7 to decrease significantly with c-Met
knockdown in U87 sh-control and U87 sh-control ∆EGFR cells (Figure 29). Ten
out of the possible sixteen proteins that were listed in Table 7 formed biological
relationships with proteins found within Ingenuity Knowledge Base’s database that
would lead to HGF expression. The majority of the proposed signaling pathways
converged on STAT3. Therefore, our data suggested that STAT3 signaling may
play a key role in regulating HGF expression in a c-Met-dependent manner.

Figure
29.
Ingenuity
pathway
analysis
of
c-Met-dependent
phosphopeptides identified by mass spectrometry that may modulate HGF
expression. Biological relationships that lead to HGF expression were explored in
Ingenuity Knowledge Base’s database from peptides that were identified by
PhosphoScan analysis as being responsive to the c-Met signal in U87 cells (Dr.
Vaibhav Chumbalkar, Dr. Oliver Bögler’s former post-doctoral fellow, assisted with
IPA analysis).
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Although STAT3 did not surface in our mass spectrometry-based screen as
a significantly changed phosphopeptide with c-Met knockdown, it was identified in
all of the cell lines that were processed for mass spectrometry analysis (Figure
30), and confirmed to decrease with c-Met knockdown in U87 and U87 ∆EGFR
cells (Figure 31A). This finding was confirmed in cell lysates from the cell lines
that were processed for Phosphoscan analysis (Figure 31B).

Figure 30. Mass spectrum of the signal transducer and activator of
transcription 3 (STAT3) Y705 peptide. This spectrum shows Y705 phosphorylation
[(K)YCRPESQEHPEADPGSAAPyLK(T)]. Peptide Index: 2345.
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Figure 31. STAT3 Y705 phosphorylation decreases with c-Met knockdown
in U87 and U87 ∆EGFR cells. (A) PhosphoScan mean intensity values (105) of
STAT3 Y705 phosphorylation in U87 sh-control cells with or without c-Met
knockdown and / or ∆EGFR expression (n = 2; duplicate samples per experiment;
mean abundance ± SEM). (B) Western blot validation of pSTAT3 Y705
phosphorylation in cells that were analyzed by mass spectrometry.

Inhibition of the c-Met and ∆EGFR signal in U87 ∆EGFR cells with AG1478
and SU11274 treatment, respectively, effectively decreased the phosphorylation
of STAT3 (Y705) and of Src (Y416) (Figure 32), a known non-receptor tyrosine
kinase that activates STAT3 by phosphorylation at Y705 (Wojcik et al., 2006).
Even though Src (Y416) phosphorylation was attenuated with EGFR and c-Met
inhibition in U87 parental cells, STAT3 (Y705) phosphorylation was not as strongly
attenuated. We also observed that STAT3 (Y705) phosphorylation did not
increase in intensity with ∆EGFR expression in U87 cells, consistent with findings
in previous reports (Huang et al., 2009).
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Figure 32. STAT3 activity decreases with c-Met and ∆EGFR inhibition in
U87 ∆EGFR cells. Western blot analysis of U87 and U87 ∆EGFR cells that were
treated for 20 h with either 0.1% DMSO, 10 μM AG1478 (EGFR and ∆EGFR
antagonist), 10μM SU11274 (c-Met antagonist), a combination of 10 μM AG1478
and 10μM SU11274, 10 μM PP2 (Src antagonist), 2.5 μM WP1193 (STAT3
antagonist), or a combination of 10 μM PP2 and 2.5 μM WP1193. Src and STAT3
inhibition with PP2 and WP1193, respectively, served as positive controls. Cells
were cultured in 10% FBS-containing media.

Taken together, these data suggest that the phosphorylation of STAT3 at
Y705 is modulated by c-Met in U87 cells, and that STAT3 may be an important
signaling effector necessary for HGF production in these cells.

STAT3 Partially Rescues Attenuated HGF and Anchorageindependent Growth of c-Met Silenced U87 ∆EGFR Cells
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Given that STAT3 most likely regulates HGF expression in response to the
c-Met signal in GBM cells, we tested if inhibition of STAT3 activity could modulate
HGF expression. We treated U87 ∆EGFR cells with WP1193, a phosphorylation
inhibitor of STAT3 Y705 (Kong et al., 2010), and analyzed HGF mRNA expression
by qRT-PCR in these cells. We found that with STAT3 Y705 inhibition that HGF
mRNA levels were attenuated (Figure 33A). The inhibition of STAT3 Y705
phosphorylation following the treatment of U87 ∆EGFR cells with WP1193 was
confirmed by western blot (Figure 33B).

Figure 33. STAT3 Y705 inhibition attenuates HGF mRNA expression in
U87 ∆EGFR cells. (A) HGF mRNA amounts were quantified in U87 ∆EGFR cells
by qRT-PCR after 16 h of being untreated (-), or after they were treated with
vehicle (0.1% DMSO) or with 2.5 μM WP1193 (STAT3 phosphorylation inhibitor).
Cells were cultured in media containing 10% FBS (* = P < 0.05; Student’s t-test
compared with DMSO-treated cells; n = 3±SEM; samples were analyzed at least
in duplicate per experiment). (B) Aliquots of the cells that were treated in (A) were
analyzed using western blotting techniques to ensure that WP1193 had
decreased STAT3 Y705 phosphorylation.
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Constitutively activate STAT3, produced by substitution of two SH2
domain cysteine residues with Ala661 and Asn664 (Bromberg et al., 1999; Ning et
al., 2001), spontaneously dimerizes to enhance STAT3’s function as a
transcription factor (Bromberg et al., 1999). We tested whether the expression of
constitutively active STAT3 (STAT3-CA) would be able to rescue the HGF
production deficit found in U87 sh-control ∆EGFR cells with c-Met knockdown. We
overexpressed an empty vector control or STAT3-CA in U87 sh-control ∆EGFR
and in U87 sh-c-Met #B2 ∆EGFR cells, and analyzed their HGF mRNA
abundance by q-RT-PCR and by western blot. We found that STAT3-CA partially
rescued HGF mRNA (Figure 34A) and protein (Figure 34B) amounts in ∆EGFRexpressing GBM cells with c-Met knockdown.

Figure 34. Constitutively active STAT3 partially rescues HGF expression in
c-Met silenced U87 ∆EGFR cells. (A) qRT-PCR quantified HGF mRNA amounts in
U87 sh-control ∆EGFR pcDNA3.1-E cells, U87 sh-control ∆EGFR STAT3-CA
cells, U87 sh-c-Met #B2 ∆EGFR pcDNA3.1-E cells, and in U87 sh-c-Met #B2
∆EGFR STAT3-CA cells. Cells were cultured in media containing 10% FBS
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(P<0.01; Student’s t-test; n = 3±SEM; samples were analyzed at least in duplicate
per experiment). (B) All cells detailed in (A) were analyzed for their HGF
expression and STAT3 Y705 phosphorylation by western blot.

In an effort to determine whether the promoter activity of HGF, which
contains a STAT3 consensus binding site in the proximal promoter at -99/-91
(TTACCGTAA; Tomida and Saito, 2004), would decrease with c-Met knockdown
in U87 cells we performed promoter assays. We initially examined if the activity of
a HGF-1029-luciferase reporter (Figure 35A) would increase compared with a
pGL2-basic construct in U87 cells. By doing this, we determined that the HGF1029-luciferase construct was functional (Figure 35B). Surprisingly, we found that
HGF promoter activity with the first -1029 bp did not decrease with silencing of cMet in U87 cells (Figure 35C). These data suggested that the HGF gene may be
regulated transcriptionally beyond the first -1029 base pairs, or that HGF
expression may be modulated at the RNA level.
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Figure 35. HGF promoter activity is unresponsive to c-Met knockdown in
U87 cells. (A) Schematic of the pGL2-HGF-luciferase (-1029 bp) reporter
construct used to examine HGF promoter activity in (B) and (C). The STAT3
consensus binding site at circa -100 bp is depicted. (B) U87 cells were transfected
with a HGF-1029-luciferase reporter construct or a pGL2-basic-luciferase reporter
construct along with a pSV-β-galactosidase construct and then harvested for
measurement of luciferase and β-galactosidase activity (± SEM). (C). Luciferase
assays measured the activity of the HGF-1029 promoter construct when
transfected into U87, U87 sh-control, U87 sh-c-Met #A2 and U87 sh-c-Met #B2
cells (normalized to β-galactosidase activity; n=2 ± SEM).

To determine if the stability of HGF mRNA was affected with c-Met
knockdown in U87 cells, we pretreated U87, U87 sh-control, U87 sh-c-Met #A2,
and U87 sh-c-Met #B2 cells with actinomycin D, a transcription inhibitor, for 1 h
and then quantified HGF mRNA levels at 0 h and 8 h by qRT-PCR. HGF did not
decay at a faster rate in U87 cells with c-Met knockdown than in U87 parental or
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U87 sh-control cells within 8 h (Figure 36). c-Myc was used as a positive control,
due to its rapid turnover rate in U87 cells (Marderosian et al., 2006). These results
fail to show a profound impact on HGF mRNA stability, and so indicate that c-Metdependent HGF regulation was most likely not due to post-transcriptional
instability of mRNA.

Figure 36. c-Met knockdown does not affect HGF mRNA stability. Q-RTPCR measured HGF mRNA amounts at 0 h and 8 h following the exposure of U87
cells to 5 ug / mL Actinomycin D (samples were analyzed in triplicate and
compared relative to cells analyzed at t0; c-myc mRNA instability served as a
positive control).

We determined if STAT3-CA could restore the loss in anchorageindependent growth that we had observed with c-Met knockdown in U87 ∆EGFR
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cells (Figure 23). By performing in vitro colony formation assays, we found that
STAT3-CA was capable of partially restoring deficits in anchorage-independent
growth found with c-Met knockdown in these cells (Figure 37). This effect was
comparable to its capability of rescuing HGF expression in c-Met knockdown cells
(Figure 34).

Figure 37. STAT3 partially rescues colony formation associated with c-Met
knockdown in U87 ∆EGFR cells. Anchorage-independent growth was assessed
using U87 sh-control ∆EGFR pcDNA3.1-E cells, U87 sh-control ∆EGFR STAT3CA cells, U87 sh-c-Met #B2 ∆EGFR pcDNA3.1-E cells, and U87 sh-c-Met #B2
∆EGFR STAT3-CA cells after 14 days in culture (* = P<0.05; Student's t-test; n =
3 ± SEM; samples were analyzed at least in duplicate per experiment).

Our results therefore suggest that STAT3 is a key signaling effector that
regulates HGF expression in response to c-Met signaling in ∆EGFR-expressing
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GBM cells, although it does not appear to be the only regulator. Other pathways
are therefore most likely required for maximal HGF expression in this model
(Figure 38). Taken together, our data suggest that the ligand-dependent and
ligand-independent activation of c-Met drives HGF expression partly via STAT3.

Figure 38. Proposed model of enhanced HGF expression via c-Met
activation in GBM cells.
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CHAPTER 6

RESULTS

THE C-MET / HGF AXIS IS UPREGULATED IN
MESENCHYMAL GBM TUMORS

104

Using IPA, we showed that STAT3 activity is necessary, but still requires
additional signaling pathways, for HGF expression in response to the c-Met signal
in GBM cells (Figure 29); a finding subsequently validated in vitro (Figure 34). The
IPA bioinformatic analysis identified that C/EBPβ and STAT3 are dependent on
the same upstream signaling effectors that are required for c-Met-dependent HGF
expression, suggesting that they may work in concert to maximally upregulate
HGF expression.
STAT3 and C/EBPβ are master regulators of the mesenchymal GBM
subtype (Carro et al., 2010). This subclass of GBM tumors is associated with a
poorer prognosis compared with proneural tumors (Phillips et al., 2006). YKL-40,
a mesenchymal signature gene, confers resistance to radiotherapy (Pelloski et al.,
2005) and is upregulated in recurrent tumors (Phillips et al., 2006). This was
consistent with an observation that many recurrent tumors tend to shift their gene
expression signature to that of the mesenchymal GBM subtype (Phillips et al.
2006). Based on our prior bioinformatic data that processed c-Met dependent
phosphopeptides in the context of HGF regulation, we were interested in
determining whether the c-Met / HGF axis is upregulated in mesenchymal GBM
tumors. TCGA GBM tumors have been classified into four subtypes by Verhaak
and colleagues (2010) based on specific signature gene sets for each GBM
subtype; with those subtypes being mesenchymal, proneural, neural, and
classical. We extracted c-Met and HGF gene expression values (Agilent platform;
TCGA’s GBM level 3 gene expression data) for each tumor that had already been
classified as one of the four GBM subclasses by Verhaak et al., 2010. Elevated cMet (Figure 39) and HGF (Figure 40) mRNA expression associated significantly
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with the mesenchymal GBM subtype when compared with tumors having a
proneural, neural, or classical assignment.

Figure 39. c-Met mRNA expression is upregulated in the mesenchymal
GBM subtype (Verhaak determined). c-Met mRNA abundance was determined in
tumors that were assigned as one of four GBM subtypes (mesenchymal,
proneural, neural, and classical) by Verhaak and colleagues (2010). Level 3
mRNA expression data was downloaded from TCGA, which was represented as a
Log10 ratio to a reference RNA (* = P<0.05; *** = P<0.001; Welsh’s t-test
compared with the mesenchymal GBM subtype; n= 200; Dr. Brian Vaillant, Dr.
Howard Colman’s former post-doctoral fellow, performed this analysis).
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Figure 40. Enhanced HGF mRNA expression associates with the
mesenchymal GBM subtype (Verhaak determined). HGF mRNA expression was
determined in tumors that were assigned a GBM subtype (mesenchymal,
proneural, neural, and classical; Verhaak et al., 2010). TCGA levels 3 mRNA
expression data were represented as a Log10 ratio to a reference RNA (*** =
P<0.001; Welsh’s t-test compared with the mesenchymal GBM subtype; n = 200;
Dr. Brian Vaillant, Dr. Howard Colman’s former post-doctoral fellow, performed
this analysis).

At the time when Verhaak and colleagues (2010) classified TCGA GBM
tumors into either mesenchymal, proneural, neural, or classical subtypes, there
were only 200 GBM tumors in the database with gene expression profiles. Since
then, the TCGA database has included gene expression data for an additional
295 tumors. Therefore, we wanted to examine whether our initial findings, which
showed that enhanced c-Met and HGF expression correlated with mesenchymal
GBM tumors, would remain robust in an analysis that made use of a larger 495
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tumor dataset. Verhaak and colleagues (2010) defined specific lists of gene sets
for the various GBM subtypes, which we used to calculate average metagene
expression values for each tumor. Tumors were then assigned to a GBM subtype
based on the highest average metagene score. We then analyzed each tumor for
their c-Met and HGF mRNA expression. In agreement with our previous data, we
found that their higher expression levels correlated with the mesenchymal GBM
subtype (Figure 41 and Figure 42, respectively).

Figure 41. c-Met mRNA expression is elevated in mesenchymal GBM
tumors (Verhaak calculated). Tumors were assigned a GBM classifier
(mesenchymal, proneural, neural, classical) according to the highest metagene
score for each GBM subtype, from lists previously defined by Verhaak et al.
(2010). c-Met mRNA expression (log10 ratios to reference RNA) levels were then
documented per tumor (*** = P<0.001; Welsh’s t-test compared with the
mesenchymal GBM subtype; n = 495; Dr. Brian Vaillant, Dr. Howard Colman’s
former post-doctoral fellow, performed this analysis).
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Figure 42. Mesenchymal GBM tumors express increased levels of HGF
mRNA (Verhaak calculated). GBM tumors (495) were designated as
mesenchymal, proneural, neural or classical as defined by gene lists reported by
Verhaak et al., 2010. TCGA HGF mRNA expression, expressed as log10 ratios to
a reference RNA, were then documented per tumor (*** = P<0.001; Welsh’s t-test
compared with the mesenchymal GBM subtype; n = 495; Dr. Brian Vaillant, Dr.
Howard Colman’s former post-doctoral fellow, performed this analysis).

Phillips and colleagues (2006) were the first authors to describe a set of
genes that classified mesenchymal, proneural, and proliferative GBM tumors.
They clearly showed that patient survival was significantly impacted if GBMs were
either mesenchymal or proliferative, compared with those patients having
proneural tumors; mesenchymal tumors had the worst prognosis. Both Phillips et
al., 2006 and Verhaak et al., 2010 identified the mesenchymal and proneural GBM
subclasses, assigning them with similar functional definitions, however their gene
lists for each of these subtypes differed. We used the gene lists described by
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Phillips et al., 2006 for mesenchymal, proneural, or proliferative GBM tumors in
the TCGA dataset to determine which subclass had the highest c-Met and HGF
expression. We found that increased levels of c-Met and HGF mRNA expression
associated most with the mesenchymal class of GBM tumors that were defined by
Phillips et al. (2006), although there was no significant difference in expression
between the mesenchymal and proliferative GBM subclasses (Figure 43 and
Figure 44, respectively). Significantly, the proneural GBMs expressed much less
c-Met and HGF than mesenchymal tumors, suggesting that survival may be
impacted with greater abundance of the c-Met / HGF axis, which is consistent with
a previous report (Kong et al., 2009).

Figure
43.
Mesenchymal
and
proliferative GBM tumors express elevated cMet mRNA levels (Phillips calculated). c-Met
mRNA expression (log10 ratios to reference
RNA) for 495 GBM tumors was downloaded
from the TCGA database. Each GBM tumor
was subclassified as a GBM subtype
(mesenchymal, proliferative, or proneural).
This was based on the highest average gene
list score per GBM subtype, as defined by
Phillips et al., 2006 (*** = P<0.001; Welsh’s ttest compared with the mesenchymal GBM
subtype; n = 495; P<0.01 when c-Met
expression was compared in proliferative
versus proneural GBMs using Welsh’s t-test;
Dr. Brian Vaillant, Dr. Howard Colman’s
former post-doctoral fellow, performed this
analysis).
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Figure 44. Increased HGF mRNA expression associates most with the
mesenchymal and proliferative GBM subtypes (Phillips calculated). HGF gene
expression values were extracted from the TCGA database for 495 GBM tumors.
Each tumor was assigned to either the mesenchymal, proliferative, or proneural
GBM subtype, according to the highest average metagene score. Gene lists per
GBM subtype were described by Phillips et al., 2006 (*** = P<0.001; Welsh’s t-test
compared with the mesenchymal GBM subtype; n = 495; P<0.05 when HGF
expression was compared in proliferative versus proneural GBMs using Welsh’s ttest; Dr. Brian Vaillant, Dr. Howard Colman’s former post-doctoral fellow,
performed this analysis).

False-discovery rates in microarray studies are high if only single datasets
are evaluated; data interpretation would need to be performed with caution
(Colman et al., 2010). Therefore, we validated our findings in an independent
sample set of GBM tumors, available in the REMBRANDT database, that were
processed on a different platform (Affymetrix gene expression platform) to that of
our previous dataset (Agilent gene expression platform). Average metagene
scores were calculated per GBM subtype for each tumor, which was based on
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Verhaak et al., 2010- determined gene lists for the four GBM subtypes. Then,
tumors were binned to a GBM subtype, and their c-Met and HGF expression
levels extracted. We found higher c-Met (Figure 45) and HGF (Figure 46)
expression levels in the mesenchymal-angiogenic GBM subclass compared with
all others. Proneural and neural tumors did not differ significantly from
mesenchymal tumors in terms of their overall c-Met expression, which was
possibly due to the presence of a few outliers in those GBM subtypes and an
inferior c-Met probe set on the Affymetrix gene expression platform.

Figure 45. Validation that higher c-Met expression levels associates with
the mesenchymal GBM subtype in an independent sample set (Verhaak
calculated). Expression data for GBM tumors were obtained from the
REMBRANDT database, which were represented as log2 transformed data after
they had been normalized to pooled normal brain. Tumors were assigned to a
GBM subtype according to their highest average metagene value per Verhaak
determined GBM subtype. Gene lists per GBM subtype were described by
Verhaak et al., 2010 (*** = P<0.001; Welsh’s t-test compared with the
mesenchymal GBM subtype; n = 180; Dr. Brian Vaillant, Dr. Howard Colman’s
former post-doctoral fellow, performed this analysis).
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Figure 46. Independent dataset validation that elevated HGF expression
levels associate with the mesenchymal GBM subtype (Verhaak calculated).
mRNA expression data for 180 GBM tumors was obtained from the REMBRANDT
database. These data were normalized to pooled normal brain expression data,
and then log2 transformed. Verhaak et al., 2010 determined which genes defined
each GBM subtype, and accordingly this list was used to calculate an average
expression score per tumor. Tumors were assigned to a GBM subtype based on
the highest average expression score, and their HGF expression levels reported
(*** = P<0.001; Welsh’s t-test compared with the mesenchymal GBM subtype; n =
180; Dr. Brian Vaillant, Dr. Howard Colman’s former post-doctoral fellow,
performed this analysis).

In summary, our results suggest that upregulation of the c-Met / HGF axis
is strongly associated with the mesenchymal GBM subtype. Since antagonists of
this receptor ligand pair are available, our data may be developed further by
performing additional basic and pre-clinical studies with an eventual goal of being
able to treat patients according to the molecular subtype of their tumor.
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CHAPTER 7

DISCUSSION
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GBM is a relentless and cruel disease. Not only is it invariably lethal, but
patients suffer loss of higher neurocognition within a very short amount of time
(Bosma et al., 2007). Conventional therapies have only slightly improved upon
patient prognosis over the past few decades, making the expedited identification
of effective targets necessary (Lassman and Holland, 2007). For these reasons,
GBM has often been given priority status. For example, GBM was the first cancer
genome analyzed by the TCGA for important genetic changes that lead to
dysregulated signaling pathways, even though it is not a very prevalent cancer
(The Cancer Genome Atlas Research Network, 2008). One such pathway is the cMet / HGF signaling axis, which has been found to be a key determinant of brain
tumor malignancy (Abounader and Laterra, 2009). In studies with a limited
number of samples, it has been shown that c-Met and HGF coexpression
increases with glioma grade (Koochekpour et al., 1997; Moriyama et al., 1998).
We showed for the first time that c-Met and HGF expression are positively
correlated in a large dataset of 495 GBMs. Importantly, our data revealed that the
highest expression levels of HGF and c-Met were found in mesenchymal GBM
tumors; the most aggressive GBM subtype that is associated with the worst
prognosis (Phillips et al., 2005). Interestingly, HGF appeared to have a stronger
differentiation for the mesenchymal GBM subgroup than c-Met. This may be due
to an inferior c-Met probe set, which will not correctly reflect the underlying
biology. Undeniably however, c-Met and HGF expression are upregulated in
mesenchymal GBMs compared with proneural, or less aggressive, GBMs.
Theoretically it would be ideal to have a unified gene set for the mesenchymal
GBM subtype, however this is limited and complicated by the fact that there are
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various gene expression platforms containing different gene-specific probe sets,
and by the statistical tests that were employed to analyze the data. Phillips et al.
(2006) and Verhaak et al. (2010) identified different gene sets that defined the
mesenchymal and proneural GBM subtypes. In agreement however, they found a
subset of GBMs with an aggressive mesenchymal-angiogenic molecular profile,
which they termed mesenchymal GBMs, and a list of genes known to modulate
normal neural development, which they named the proneural GBM subtype. Both
authors’ mesenchymal gene list included YKL-40, a mesenchymal marker protein
(Carro et al., 2010) associated with a poor outcome for GBM patients (Colman et
al., 2010; Pellowski et al., 2005). Recurrent GBMs, whether proneural or
proliferative, tend to shift their molecular profile to that of a mesenchymal
signature (Phillips et al., 2005). These data suggest that the c-Met / HGF signaling
axis might be a good target for the treatment of primary mesenchymal GBMs, and
for recurring GBMs. With additional preclinical studies into the applicability of
these findings, we may be a step closer to adding another element of
personalized patient care for individuals with GBM.
The mesenchymal or aggressive behavior of GBM usually includes local
invasion and neo-angiogenesis, which are phenotypic hallmarks of glioma
malignancy (Carro et al., 2010). Interestingly, we found that the gross morphology
of U87 cells changed from a mesenchymal-like to an epithelial-like shape
following knockdown of c-Met, and also with the expression of kinase-deficient cMet mutants. These data indicate that the expression and activity of c-Met may be
important components necessary for preservation of the mesenchymal-like
appearance, and possibly even mesenchymal behavior, of GBM cells.
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Another important novel finding of our study is that c-Met signaling
regulates the expression of HGF in GBM cells. In a complementary study,
Abounader

and

colleagues

(2001)

showed

that

c-Met

expression

is

transcriptionally induced by HGF-mediated c-Met activation in GBM cells.
Together these findings emphasize the importance of the autocrine c-Met / HGF
signaling axis in GBM. Perpetuation of an autocrine signal has also been found in
many other ligand-receptor systems, including EGFR signaling, as EGFR autoinduces its own expression in various cancer cell lines (Clark et al., 1985;
McCulloch et al., 1998; Seth et al., 1999), and of its ligands, HB-EGF, epiregulin,
and amphiregulin (Chu et al., 2005). Our finding that c-Met signaling modulates
the expression of its own ligand in GBM cells, suggests that c-Met-dependent
biological

programs,

such

as

cellular

proliferation,

mobility,

invasion,

angiogenesis, and tumorigenicity (Abounader and Laterra, 2009) may be amplified
in GBM as a consequence of this regulation.
That these interconnections at the level of signaling and expression are
relevant to the biology of the disease is supported by our findings in culture and
animal models. We found that c-Met expression was necessary for U87 cells to
form colonies in three-dimensional cultures, and to maintain the tumorigenic
potential of orthotopic U87 xenografts. HGF expression was attenuated with c-Met
knockdown in vitro to the same extent that tumorigenicity decreased in vivo. It is
therefore possible that the two findings are mechanistically connected, and that
regulation of the c-Met / HGF autocrine signal plays a key role in the
tumorigenicity of c-Met-dependent U87 cells. In agreement with what we found,
others have shown that the tumorigenicity of intracranial U87 xenografts was
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attenuated with c-Met (Martens et al., 2006) or HGF (Pillay et al., 2009)
antagonism. That this pathway may not be present in all GBM cells is suggested
by the work of Martens and colleagues (2006), who showed that a non-c-Metdependent GBM cell line, meaning that it did not coexpress c-Met and HGF
(Beroukhim et al., 2007), did not respond to anti-c-Met therapy in vivo. This finding
was further explored in vitro by Beroukhim and colleagues (2007). They provided
data to suggest that enhanced cytotoxicity could only be achieved with a c-Met
TKI in GBM cells that coexpressed c-Met and HGF. Strikingly, when Lal and
colleagues (2005) cotargeted c-Met and HGF with U1/ribozymes in preestablished
intracranial U87 xenografts, and then subjected the mice to hypofractionated γradiation, 80% of the mice survived long-term. The efficacy of non-targeted
standard chemotherapeutic agents similarly enhanced the survival of mice when
used in conjunction with an anti-HGF neutralizing antibody in U87 cells and
xenografts (Jun et al., 2007). Taken together, these data suggest that targeting
the c-Met signaling axis in GBMs that are dependent upon the autocrine HGF
signal for their anchorage-independent growth and tumorigenicity, either before or
after standard care treatment regimens, may be a powerful strategy for therapy of
these tumors. However, we would also like to point out the limitation that not all
GBMs, or even all cells in any one GBM, are likely to be susceptible to this
approach, and that careful analysis of the expression of both c-Met and HGF
needs to precede application of such therapies.
In cancer cell lines, such as thyroid carcinoma, GBM (Reznik et al., 2008),
NSCLC (Xu et al., 2010), bladder carcinoma (Yamamoto et al., 2006), and breast
carcinoma (Bonine-Summers et al., 2007; Mueller et al., 2010), a significant
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amount of pathway crosstalk occurs between the EGFR and c-Met signaling axes.
Not only does the EGFR transactivate the c-Met receptor in various cancer cell
lines (Bergström et al., 2000; Fischer et al., 2004), but c-Met signaling also
modulates the activity of the EGFR in c-Met-dependent gastric cancer cells
(Bachleitner-Hofmann et al., 2008). Oncogene switching also takes place between
c-Met and EGFR, where alternate receptor activation is a mechanism employed
by cancer cells to compensate for loss of function of the other receptor (Mueller et
al., 2008; Bachleitner-Hofmann et al., 2008). As a result, the activity of c-Met has
been reported to be a key factor circumventing the effectiveness of EGFR TKIs
(Tang et al., 2008). Therefore, greater therapeutic efficacies have been
accomplished by cotargeting c-Met and EGFR in tumors that have become
resistant to EGFR TKIs (Tang et al., 2008). Our laboratory has shown that Y1235
of c-Met is activated by EGF-stimulated EGFR in GBM cells (Chumbalkar et al.,
2011), which suggests that crosstalk between c-Met and EGFR may play an
important role in GBM, which may ultimately be targetable.
We have shown that many GBMs contain a robust HGF autocrine loop that
is inducible through c-Met signaling, and Abounader et al. (2001) provided
evidence that HGF-mediated c-Met activation induces the expression of the c-Met
gene. As a result of enhanced HGF expression, dysregulated HGF / c-Met
signaling most likely leads to c-Met overexpression. Once overexpressed,
receptors may be activated in a ligand-independent manner due to their closer
proximity with other RTKs (Mineo et al., 1999). This occurs especially when a
receptor is a preferential target of those nearby receptors, such as is the case with
c-Met activation being a preferred downstream signaling pathway for the ∆EGFR
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(Chumbalkar et al., 2011; Huang et al., 2007; Pillay et al., 2009). It is still unclear
whether ∆EGFR transactivates c-Met directly, or whether intermediary signaling
effectors are necessary for ∆EGFR-mediated c-Met activation in GBM cells, but
we do know that they associate in a complex (data not shown). We showed that cMet activation by ∆-EGFR enhances HGF expression, which provides a rationale
for targeting HGF in GBMs that express the ∆EGFR. However, Pillay et al. (2009)
showed that HGF antagonism of U87 ∆EGFR-expressing intracranial xenografts
was ineffective. This was contrary to what they found when they treated U87 cells,
and U87 cells that expressed the WT EGFR, with the same anti-HGF monoclonal
antibody. We propose that HGF neutralizing antibody treatment of GBMs
expressing ΔEGFR may not reach therapeutic efficacy levels, due to incomplete
neutralization of the higher amounts of HGF that are most likely being produced in
these tumors. This idea is supported by a remarkable reduction in tumorigenicity
when ∆EGFR-driven GBM xenografts are treated with anti-HGF and anti-EGFR
therapies in combination, compared with either agent alone (Lal et al., 2009; Pillay
et al., 2009).
Depending on the cellular context, the c-Met / HGF signaling axis can
promote either survival or apoptosis (Trusolino et al., 2010). Interestingly, HGF
has been called ‘tumor cytotoxic factor’, because excessive amounts of this
cytokine may induce apoptosis in various cancer cell lines (Trusolino et al., 2010).
It has been suggested that higher levels of HGF may titre out the available ligandbinding domains of c-Met on the cell surface, thereby liberating bound FAS, a
death receptor that often associates with c-Met as a survival mechanism, and
hence promote apoptosis (Trusolino et al., 2010). However, we and others have
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shown that ∆EGFR-expressing GBM cells express high levels of BCL-XL (Nagane
et al., 1996), which may likely serve to promote cell survival while still maintaining
constitutive ligand-dependent and ligand-independent c-Met activity.
We found that c-Met was required by ∆EGFR to maintain its elevated
production of HGF in U87 cells. We also showed that when c-Met’s expression
was silenced in U87 cells expressing ∆EGFR, the tumorigenicity of intracranial
xenografts was significantly compromised. In fact, ∆EGFR lost all oncogenic
potency with c-Met knockdown. These findings suggest that targeting c-Met in cMet-addicted GBMs that express the ∆EGFR, such as in a subset of tumors
belonging to the mesenchymal GBM subgroup, may be an effective treatment
strategy. However, very few mesenchymal GBMs were detected by Verhaak and
colleagues (2010) to express the ∆EGFR. We predict that a large number of
∆EGFR-expressing GBMs were not discovered in their study, due to the scanty
expression of ∆EGFR in the bulk of a tumor that limits its detectability (Jungbluth
et al., 2003; Wiesner et al., 2009), and due to TCGA’s sample exclusion criteria
(Verhaak et al., 2010). Therefore, it is possible that the subset of mesenchymal
GBMs that express ∆EGFR may be larger than reported by Verhaak et al. (2010).
Using different techniques, other investigators have found that approximately 30%
of GBMs contain the ∆EGFR mutation (Hwang et al., 2011), compared with the
7% of GBMs reported by Verhaak et al. (2010).
c-Met-dependent effectors of HGF expression that were identified in our
phosphotyrosine-based mass spectrometry screen, mostly merged on STAT3.
Others have found that HGF promoter activity is upregulated via STAT3 signaling
in a variety of cancer cell lines (Tomida and Saito, 2004; Wojcik et al., 2006).

121

Interestingly, STAT3 expression is critical for maintenance of the mesenchymal
gene expression signature, and of the associated aggressive phenotype of GBM
(Carro et al., 2010). In agreement, aberrant STAT3 activity correlates with a poor
survival prognosis for GBM patients (Birner et al., 2010). Zhang et al. (2002)
provided evidence to suggest that STAT3 is a crucial component of the c-Met
signal in cancer cells, which is required for anchorage-independent colony
formation and tumor growth. We found that STAT3 activity was attenuated with cMet knockdown in U87 ∆EGFR cells, and that the loss in anchorage-independent
growth of these cells could partially be restored via constitutively active STAT3
expression. These data suggested that c-Met-mediated STAT3 signaling plays a
key role in maintaining anchorage-independent growth of U87 cells expressing
∆EGFR.
It has been suggested that STAT3 Y705 phosphorylation is not significantly
enhanced by ∆EGFR in GBM cells (Huang et al., 2009). However, the STAT3
signal is recruited by ∆EGFR to induce the transformation of astrocytes (de la
Iglesia et al., 2008). Additionally, proliferation and survival mechanisms
associated with ∆EGFR expression in GBM cells are strengthened by STAT3
signaling (Huang et al., 2009). We found that activated STAT3 partially modulates
HGF expression in U87 ∆EGFR-expressing cells. It is possible that HGFstimulated c-Met activates STAT3 within the perinuclear compartment of U87 and
U87 ∆EGFR cells, as this mechanism of compartmentalization of c-Metdependent STAT3 activation has been employed by other cancer cells
(Kermorgant et al., 2008). Taken together, these data suggest that ∆EGFR usurps
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the c-Met-dependent STAT3 signal in U87 cells, to partly promote oncogenicity via
increased HGF expression.
STAT3 signaling was necessary, yet insufficient, to modulate HGF
expression in U87 cells, and in U87 cells expressing ∆EGFR. Using IPA, we
showed that C/EBPβ and STAT3 share upstream signaling molecules that
regulate HGF expression in U87 and U87 ∆EGFR-expressing cells in a c-Metdependent manner.

Similarly to STAT3, C/EBPβ is a master regulator of the

mesenchymal GBM subtype (Carro et al., 2010). These data suggest that
activation of the C/EBPβ pathway will most likely be required, in addition to
STAT3 signaling, in order to maximally upregulate the expression of HGF in cMet-dependent GBM cells.
In summary, our data have highlighted the significant contribution of
dysregulated c-Met pathway signaling, and of c-Met and ∆EGFR crosstalk, to
GBM tumorigenesis. We have identified a new element in this network, the
positive feedback on HGF expression by c-Met signaling, and connected it to the
already known signal coming from ∆EGFR to c-Met. Our data show that this is an
important component of the network for tumorigenesis, and by implication may
represent an opportunity for therapy of tumors where these signals are important,
the mesenchymal GBMs.
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